 
  
  
 
 
Final Version 2.0  Protocol: TRIF-2101   Page 1 of 88 PROTOCOL TITLE
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO 
CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., [LOCATION_003]),  IN THE TREATMENT OF ACNE VULGARIS 
 
CLINICAL STUDY PROTOCOL 
 
Protocol Number:  TRIF-2101 
Protocol Version Number: 2.0 
Protocol Version Date: 30JUNE2022 
Study Sponsor:  Teva Pharmaceuticals, Inc. 
 
PROTOCOL APPROVAL 
 I am aware of, and agree to comply with, all of the procedures contained within this protocol and 
requirements of applicable regulatory agencies: 
 
Sponsor Representative 
 Nageshwar R. Thudi Ph.D.  Vice President, Global Gx. and 
Biosimilar - Clinical Development & Operations 
Teva Pharmaceuticals, Inc.   Signature/Date 
 
Sponsor Representative  Corrine Dias  Associate Director, Global Gx.  - Signature/Date 
  

  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 2 of 88 Clinical Development & Operations 
Teva Pharmaceuticals, Inc. 
Medical Monitor  Angelo Secci, MD Catawba Research  Signature/Date 
Statistical Consultant  
 Charles Bon President Biostud
y Solutions, LLC Signature/Date 
CRO Representative 
 Chris Driskill Clinical Project Manager Catawba Research Signature/Date 
  Chris 
DriskillDigitally signed by [CONTACT_531983]: 2022.07.20 12:31:52 -04'00'Angelo SecciDigitally signed by [CONTACT_531984]: 2022.07.20 14:35:22 -04'00'
Charles BonDigitally signed by [CONTACT_531985]: 2022.07.20 16:34:11 -04'00'
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690655] 
Sponsor:  
Teva Pharmaceuticals, Inc.  [ADDRESS_690656] Research Organization:  Chris Driskill Clinical Project Manager  Catawba Research,  [ADDRESS_690657]  Charlotte, NC [ZIP_CODE]  Office: Cell: [PHONE_11000]  Fax: [PHONE_11001]  Email: [EMAIL_10154]   
Statistics Data Management and Medical 
Writing:  Soumitra Chowdhury Executive Vice-President, Data and Analytics Veranex [ADDRESS_690658] Princeton, NJ  [ZIP_CODE] Phone: ([PHONE_11002] Ext.103 Cell: ([PHONE_11003] Email: [EMAIL_10155]  IWRS Vendor:  Uma Janapareddy Founder & MD SyMetric No. 51, [ADDRESS_690659] HAL 2
nd Stage 
Bengaluru – 560 008, India Phone: [PHONE_11017] Email: [EMAIL_10156] 
 Medical Monitor: 
 Angelo Secci, MD [ADDRESS_690660], Wilmington, NC [ZIP_CODE] Phone: ([PHONE_11004] Email: [EMAIL_10157]  Drug Labeling, Packaging and Shippi[INVESTIGATOR_117884]:  Denis Bartle Associate Director, Warehouse (R&D) Actavis Laboratories UT, Inc. [ADDRESS_690661] Salt Lake City, UT [ZIP_CODE], [LOCATION_003] 
Phone: [PHONE_11005] 
Fax: [PHONE_11006] Email: [EMAIL_10158]  Retention Samples Storage Facility:  Glenn Bullett BioRepository Resources, LLC [ADDRESS_690662] New Providence, NJ [ZIP_CODE] Phone: ([PHONE_11007] Fax: ([PHONE_11008] 
www.brr.us.com 
Email: [EMAIL_10159]   Independent Statistical Consultant:  Charles Bon President Biostudy Solutions, LLC [ADDRESS_690663],  Wilmington, NC [ZIP_CODE] Phone:  ([PHONE_11009] Fax: ([PHONE_11010] Email: [EMAIL_10160]  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690664] (IRB): 
 Salus IRB [ADDRESS_690665] Austin, TX [ZIP_CODE] Phone: [PHONE_11011]  Fax: [PHONE_11012]  
  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690666] ACEBO CONTROLLED, PARALLEL-DESIGN 
GROUP STUDY, TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC.) TO AKLIEF® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., [LOCATION_003]) IN THE TREATMENT OF ACNE VULGARIS and agree it contains all the necessary information for conducting this study safely. I will conduct this study in strict accordance with this protocol, ICH guidelines for Good Clinical Practice (GCP), the Code of Federal Regulations, local regulatory and ethical guidelines. I will attempt to complete the study within the time designated. 
I will ensure the rights, safety and welfare, of subjects under my care are protected. I will ensure 
control of the drugs under investigation in this study. 
I will provide access to the protocol and all other study-related information supplied by [CONTACT_531986]. I will discuss this information with them to assure that they are adequately informed regarding the drug and conduct of the study. 
I agree to keep records on all Subject information (case report forms, shipment and drug return 
forms and all other information collected during the study) and drug disposition in accordance with FDA regulations. I agree to retain and maintain strict accountability of the Investigational Medicinal Products supplied to the study site. 
I will not enroll any subjects into this study, until IRB/IEC (Independent Review 
Board/Institutional Ethics Committee) approval and Sponsor’s approval are obtained for protocol. 
 
____________________  __________________  
Principal Investi gator Si gnature/Date 
 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 6 of 88  TABLE OF CONTENTS 

PROTOCOL TITLE ................................................................................................................ .............. 1 
PROTOCOL APPROVAL ............................................................................................................. ....... 1
CONTACT [CONTACT_351110] .................................................................................................................. ................. 3 
PRINCIPAL INVESTIGATOR [INVESTIGATOR_473456] .................................................................................. 5 
TABLE OF CONTENTS ............................................................................................................. ......... 6
LIST OF ABBREVIATIONS ......................................................................................................... .... 10
STUDY SYNOPSIS ................................................................................................................ ............ 12 
1INTRODUCTION AND BACKGROUND ............................................................................... 23 
2STUDY OBJECTIVES ..............................................................................................................  23
3Study Overview ................................................................................................................ .......... 24 
4Study Visit Schedule .......................................................................................................... ........ 27
5STUDY POPULATION ............................................................................................................. 28
5.1Number of Subjects ............................................................................................................ ........ 28
5.1.1Inclusion Criteria ............................................................................................................ .....28
5.1.2Exclusion Criteria ............................................................................................................ ....31
5.1.3Prohibited Medications, Procedures, and Activities ...........................................................34 
5.1.4Precautions ................................................................................................................... .......40
5.1.5Subject Disposition and Discontinuation ............................................................................41 
6SAFETY AND TOLERABILITY EVALUATIONS ................................................................ 42 
6.1General Safety Evaluations .................................................................................................... .... 43
6.1.1Physical Examination .......................................................................................................... 43
6.1.2Vital Signs ................................................................................................................... ........44
6.1.3Pregnancy Test ................................................................................................................ ....44
6.2Concomitant Medications ....................................................................................................... .... 45
6.3Evaluation of Signs/Symptoms of Local Irritation/Application Site Reactions ......................... 45 
6.4Adverse Events ................................................................................................................ ........... 46 
6.5COVID-19 symptom screening .................................................................................................. 4 7
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 7 of 88 6.6Lack of Treatment Effect (LOTE) .............................................................................................. 47
7CLINICAL EVALUATIONS .................................................................................................... 47 
7.1Investigator’s Global Assessment (IGA) ................................................................................... 48 
7.2Lesion Counts ................................................................................................................. ............ 48 
8STUDY VISITS (See Study Visit Schedule) ............................................................................. 49 
8.1Visit 1: Screening and Baseline (Day 0) .................................................................................... 49 
8.2Visit 2: First Interim (Week 4; Day 28 ± 4 Days) ...................................................................... 52 
8.3Visit 3: Second Interim (Week 8; Day 56 ± 4 Days) ................................................................. 53 
8.4Visit 4: End of Treatment (Week 12; Day 84 ± 4 Days) ............................................................ 54 
8.5Unscheduled Visits and Early Discontinuation Visit ................................................................. 55 
8.6Premature Termination of Study/Study Site .............................................................................. 55 
8.7Early Termination of a Subject ................................................................................................ .. 56
9STUDY TREATMENT, DESCRIPTION AND ALLOCATION ............................................. 56 
9.1Investigational Medicinal Products (IMP) Description .............................................................. 56 
9.2Storage and Handling Conditions ...............................................................................................  57
9.2.1Packaging, Blinding and Labeling ......................................................................................57 
9.2.2Randomization ................................................................................................................. ....58
9.2.3Subject Screening Number ..................................................................................................59 
9.3Treatment Assignment .......................................................................................................... ..... 59
9.4Administration of Investigational Medicinal Product ................................................................ 59 
9.5Assessment of Compliance ...................................................................................................... .. 59
9.6Investigational Medicinal Product Accountability ..................................................................... 60 
9.7Retention of Study Drug Samples .............................................................................................. 61
9.8Return of Clinical Supplies ................................................................................................... ..... 62
9.9Additional Supplies Provided by [CONTACT_154034] .......................................................................... 62 
10STATISTICAL METHODS ...................................................................................................... 63 
10.1Scientific and Statistical Considerations of the Study Design .............................................. 63 
10.1.1Sample Size Rationale ..................................................................................................63 
10.1.2Unblinding Procedures .................................................................................................64 
10.1.3Significance Level ........................................................................................................65 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 8 of 88 10.2Datasets to be Analyzed ....................................................................................................... . 65
10.3Measures ...................................................................................................................... ......... 66
10.3.1Demographics and Screening/Baseline/Randomization Characteristics ......................66 
10.3.2Safety Assessment ........................................................................................................66 
10.3.3Efficacy Assessment .....................................................................................................66 
10.4Concomitant Medication ...................................................................................................... 6 7
10.5Summary of Subjects who discontinued prematurely .......................................................... 68 
11ADVERSE EVENTS ................................................................................................................ . 68
11.1Recording of Adverse Events ............................................................................................... 68 
11.1.1Assessment of Severity ................................................................................................70 
11.1.2Relationship to Study Medication ................................................................................70 
11.2Serious Adverse Events ........................................................................................................  71
11.2.1Expectedness ................................................................................................................72 
11.3Reporting of Serious Adverse Events (SAEs) ...................................................................... 72 
11.4Pregnancy ..................................................................................................................... ........ 75
11.5Follow Up of Subjects ......................................................................................................... . 76
11.6Medication Errors and Special Situations ............................................................................. 77 
11.7Reconciliation of SAEs & Pregnancy ................................................................................... 77 
11.8Safety Considerations during COVID-19 Pandemic ............................................................ 77 
12ETHICS ........................................................................................................................ .............. 78 
12.1IRB/Ethics Committee ..........................................................................................................  78
12.2Ethical Conduct of the Study ................................................................................................ 7 8
12.3Informed Consent/Assent ..................................................................................................... 7 9
12.4Subject Confidentiality ....................................................................................................... .. 80
13DOCUMENTATION .................................................................................................................  80
13.1Site Regulatory Documents Required for Initiation ............................................................. 80 
13.2Maintenance and Retention of Records ................................................................................ 80 
13.3Data Collection and Reporting ............................................................................................. 81 
13.4Primary Source Documents .................................................................................................. 82 
13.5Study Monitoring .............................................................................................................. .... 83
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 9 of 88 13.6Audits and Inspections ........................................................................................................ .. 83
13.7Modifications to the Protocol ............................................................................................... 8 3
14Completion of Study ........................................................................................................... ....... 84
15REFERENCES .................................................................................................................... ....... 84
15.1APPENDIX I: Revision History ........................................................................................... 86 
15.2APPENDIX II: AKLIEF-trifarotene cream package insert .................................................. 87 
 
 
  
  
 
 
Final Version 2.0  Protocol: TRIF-[ADDRESS_690667] Research Or
ganization/Clinical Research Or ganization  
eCRF Electronic Case Report Form EDC Electronic Data Capture FDA Food and Dru
g Administratio n 
GCP Good Clinical Practice hCG Human Chorionic Gonadotropi
n 
HEENT Head, E yes, Ears, Nose and Throat 
HIPAA Health Insurance Portabilit y and Accountabilit y Act 
IAF ICF Informed Assent Form 
Informed Consent Form 
IGA Investi
gator’s Global Assessment 
ICH International Council for Harmonisation IEC Independent Ethics Committee IRB Institutional Review Boar
d 
IUD Intrauterine Device LOCF  Last Observation Carried Forwar
d 
LOTE Lack of Treatment Effect MedDRA Medical Dictionar
y for Re gulator y Activities 
mITT Modified Intent to Treat NSAID Non-Steroidal Anti-Inflammator
y Drug 
OTC Over the Counte r 
PP Per Protocol RLD SMMP Reference Listed Drug 
Safet
y and Medical Monitorin g Plan 
SAE Serious Adverse Event SARS-CoV-2 Severe Acute Respi[INVESTIGATOR_13521]
y Syndrome Coronavirus 2 (COVID) 
SAP Statistical Anal ysis Pla n 
SOP Standard Operatin g Procedure 
U.S. [LOCATION_002] 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 11 of 88  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 12 of 88 STUDY SYNOPSIS 
Protocol Number: TRIF-2101 
 
Version and Date of Protocol: Final Version 1.0, Dated 11-MAY-2022  
Title of Study:   A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, 
PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC.) TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., [LOCATION_003]) IN THE TREATMENT OF ACNE VULGARIS 
 
Sponsor:  Teva Pharmaceuticals, Inc.  
   [ADDRESS_690668], Bldg. A, 
   Parsippany NJ [ZIP_CODE], [LOCATION_003] 
 
Clinical Research Organization:  Catawba Research   
         [ADDRESS_690669] 
        Charlotte, NC [ZIP_CODE] [LOCATION_003] 
 
Treatment Duration : The study treatment period will last for 84 days (12 weeks). A window 
period of ± 4 days will be considered acceptable for each scheduled visit following the screening/baseline visit. 
 Test Product :  TRIFAROTENE CREAM, 0.005% (MANUFACTURED BY [CONTACT_531987], UTAH FOR TEVA PHARMACEUTICALS, INC.) 
 Reference Listed Product : AKLIEF
® (TRIFAROTENE 0.005% CREAM) (GALDERMA 
LABORATORIES, L.P., [LOCATION_003])  
 Placebo Control :  Vehicle cream (MANUFACTURED BY [CONTACT_531988], 
UTAH FOR TEVA PHARMACEUTICALS, INC.)   
 
Study Phase:  Bioequivalence (BE) study with clinical endpoint  
 Study Site(s):  This study will be conducted at multiple centers in the [LOCATION_003] and in Belize. 
 Dose and Mode  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 13 of 88 of Administration:  Subjects will be instructed to apply enough investigational drug product to 
lightly cover the entire affected areas of the face once daily at bedtime for 84 days +/-4 days.  
 
Objectives:  To evaluate the clinical therapeutic equivalence of TRIFAROTENE 
CREAM, 0.005% (and the Reference Listed Product, AKLIEF® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., [LOCATION_003]) in the treatment of acne vulgaris. 
  
To demonstrate the superiority of the efficacy of the test and reference products over that of the placebo control in the treatment of acne vulgaris.   
Design:   To compare the safety of Test, Reference, and Placebo treatments in patients 
with acne vulgaris. 
 Subjects in this randomized, double-blind, three-arm, placebo controlled, 
parallel-design, multi-site study will be randomly assigned in a 1:1:[ADDRESS_690670] or placebo control, respectively.  
 
Clinical Evaluations will be performed at: 
Visit 1: Screening/Baseline Visit (Day 0;  Visit 2: First Interim Visit (Week 4 / Day 28 ± 4 Days);  Visit 3: Second Interim Visit (Week 8 / Day 56 ± 4 Days);  Visit 4: End of Treatment Visit (Week 12 / Day 84 ± 4 Days)  
Subjects will be admitted into the study after informed consent/assent has 
been obtained, a medical history and physical examination (with vital signs) have been performed and inclusion/exclusion criteria have been met. Subjects must have a clinical diagnosis of acne vulgaris to qualify for inclusion in this study. 
Each Subject will be randomly assigned in a double-blind fashion in a 1:1:[ADDRESS_690671] or the placebo control. 
The treatment area of enrolled subjects will be assessed at all clinic visits, 
including counts of the facial comedones (open and closed), papules, 
pustules, nodulocystic lesions (nodules and cysts), the Investigator’s Global Assessment (IGA) and the signs and symptoms of irritation (application site reaction) will be assessed. 
Safety will be assessed by [CONTACT_531989], application 
site reaction assessments; urine pre gnancy test (for females of childbearing 
potential) and physical examinations including vital signs.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 14 of 88  
Unscheduled Visits are allowed at any time, for any reason, if in the Principal 
Investigator’s opi[INVESTIGATOR_1649], it is warranted. If the Unscheduled Visit is due to an adverse event (AE), the Principal Investigator [INVESTIGATOR_531934]. If a Subject is discontinued from the study during an Unscheduled Visit, the Unscheduled Visit will be referred to as an Early Discontinuation Visit and all procedures scheduled for the Early Discontinuation Visit will be performed.  
 
 Study Population :  
  
Inclusion Criteria 
1) Male or non-pregnant, non-lactating female aged  12 and  40 years with a clinical 
diagnosis of acne vulgaris. 
2) Subjects who are 18 years of age or older (up to the age of 40) must have provided IRB/IEC 
approved written informed consent. Subjects [ADDRESS_690672] provided IRB/IEC approved written assent; this written assent must be accompanied by [CONTACT_2717]/IEC approved written informed consent from the Subject’s legally acceptable representative (i.e., parent or guardian). In addition, all Subjects or their legally acceptable representatives (i.e., parent or guardian) must sign a HIPAA authorization. 
3) Subjects must have  25 non-inflammatory lesions (i.e., open and closed comedones) AND  
20 inflammatory lesions (i.e., papules and pustules) AND  2 nodulocystic lesions (i.e., 
nodules and cysts), at screening/baseline on the face.  
(a) For the purposes of study treatment and evaluation, these lesions should be 
limited to the facial treatment area. All lesions will be counted, including those present on the nose. Subjects may have acne lesions on other areas of the body which will be excluded from the count and the Investigator’s Global Assessment (IGA) evaluation (e.g., on the back, chest and arms). 
4) Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as 
per the Investigator’s Global Assessment (IGA) (per Table 1 below) at screening/baseline.  Acne vulgaris should be stable (for at least 3 months prior to screening), with minimal variation from day to day and within each day, in the opi[INVESTIGATOR_121479]. 
 Table 1: Investi
gator’s Global Assessment (IGA) Scale fo r Acne Vul garis 
Grade Descriptio n 
[ADDRESS_690673] clear; rare non-inflammatory lesions with no more 
than one small inflammator y lesio n 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 15 of 88 2 Mild severity; greater than Grade 1; some non-inflammatory 
lesions with no more than a few inflammatory lesions (papules/pustules onl
y, no nodular lesions) 
3 Moderate severity; greater than Grade 2; up to many non-
inflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion 
4* Severe; greater than Grade 3; up to many non-inflammatory 
lesions and may have some inflammatory lesions, but no more than a few nodular lesions 
* The eCRF will allow for reporting by [CONTACT_68567] 4 with treatment. Acne vulgaris subjects with nodulocystic acne are not to be enrolled in the study. Subjects who worsen beyond Grade 4 will be described in the safety evaluation. 
Note: Counts of nodules and cysts will be reported separately and not included in the 
inflammatory or non-inflammatory lesion counts. 
5) Subjects must be willing to refrain from using all other topi[INVESTIGATOR_531935] 12-week treatment period, other than the investigational product. 
6) Female subjects of childbearing potential (*WOCBP) must not be pregnant or lactating at the 
time of screening/baseline visit as documented by a negative urine pregnancy test with a sensitivity to at least 25 mIU/ml hCG . 
*Female subjects of childbearing potential (WOCBP) are defined as sexually mature women 
without prior hysterectomy, or who have had any evidence of menses in the past [ADDRESS_690674] 12 or more months are still considered to be of childbearing potential, if the amenorrhea is possibly due to other causes, including prior chemotherapy, anti- estrogens, or ovarian suppression. Postmenopausal women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or women who have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy with surgery at least 4 weeks prior to randomization) are not considered WOCBP. Subjects who have undergone tubal ligation are NOT considered as surgically sterile. 
7)  Female subjects of childbearing potential must be willing to use an acceptable form of birth 
control during the study from the day of the first dose administration to [ADDRESS_690675] administration of study drug.     
a) For the purposes of this study the following are considered acceptable methods of birth 
control: oral or injectable contraceptives, contraceptive patches, medroxyprogesterone 
acetate (ex. Depo-Provera
®) with stabilized use for at least 3 months, vaginal 
contraceptive (ex. etonogestrel/ethinyl estradiol vaginal ring (ex. NuvaRing®), 
contraceptive implant with etonogestrel or equivalent, double barrier methods, (e.g. 
condom and spermicide), intrauterine device (IUD),  true abstinence (if in line with 
subject’s lifestyle).  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 16 of 88 b) If a subject who was abstinent becomes sexually active during the study, a 2nd acceptable 
method of birth control should be used and documented. 
c) Subjects on hormonal contraception must be stabilized on the same type for at least three 
months prior to enrollment in the study and must not change the method during the study. A sterile sexual partner is not considered an adequate form of birth control. 
8) Female subjects who are premenarchal, surgically sterilized (by *hysterectomy or bilateral 
oophorectomy) or postmenopausal for at least 1 year (defined as women who have been amenorrheic for at least 12 consecutive months, without other known or suspected primary cause).  
9) All male subjects must agree to use accepted methods of birth control with their partners, from 
the day of the first dose administration to [ADDRESS_690676]’s lifestyle.  Female partners should use an acceptable method of birth control as described in the above criteria 7.  
10) Subjects must be willing and able to understand and comply with the requirements of the 
protocol, including attendance at all required study visits and refraining from the use of all other topi[INVESTIGATOR_531936] 12-week treatment period. 
11)  Subjects must be in good health and free from any clinically significant disease, which may 
interfere with the evaluation of acne vulgaris or the administration of the investigative product.  
12) Subjects who use make-up must have used the same brands/types of make-up for a minimum 
period of [ADDRESS_690677] agree to not change make-up brand/type or frequency of use throughout the study. 
 Exclusion Criteria  
1) Female subjects who are pregnant, lactating or planning to become pregnant during study 
participation.  
2) Subjects with a history of hypersensitivity or allergy to trifarotene, tretinoin, retinoids, or any 
of the study medication ingredients. 
3) Subjects with the presence of any skin condition that would interfere with the diagnosis or 
assessment of acne vulgaris (such conditions include but are not limited to the following on the face: rosacea, dermatitis, psoriasis, squam ous cell carcinoma, eczema, acneiform eruptions 
caused by [CONTACT_6589], steroid or corticosteroid-induced acne, steroid folliculitis, or bacterial folliculitis, auto-immune disease, perioral dermatitis, carcinoid syndrome, mastocytosis, acneiform eruptions caused by [INVESTIGATOR_214465]-up and medication, facial psoriasis and facial eczema). 
4) Subjects with nodulocystic acne (> 2 nodules and cysts). [Nodules or cysts defined as; deep-
seated in the skin (i.e., centered in the der mis or subcutis) and an inflammatory lesion greater 
than or equal to 5 mm in diameter], acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.) or acne vulgaris requiring systemic treatment. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 17 of 88 5) Subjects with excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would 
interfere with diagnosis or assessment of acne vulgaris.  
6) Subjects with tattoos or excessive facial scarring that, in the Investigator’s opi[INVESTIGATOR_1649], may 
interfere with the evaluation of the patient’s acne.  
7) Subjects who have used within 6 months prior to screening/baseline oral retinoids (e.g., 
Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day 
(multivitamins are allowed). These treatments with oral retinoids or Vitamin A supplements are prohibited during the study participation. 
8) Subjects who have used within 1 month prior to screening/baseline neuromuscular blocking 
agents or androgen receptor blockers (e.g., spi[INVESTIGATOR_8407], Flutamide etc.). 
9) Subjects who have had laser therapy, electrodessication phototherapy and or cosmetic 
procedures (e.g., ClearLight 
® BOTOX, Filler, micro needling) to the facial area within 6 
months prior to study entry. 
10) Subjects who have had facial cosmetic procedures (e.g., facials) or application of cosmetic 
products (cosmetics, makeup or facial products that have a strong drying or possible interactive effect, particularly preparations containing spi[INVESTIGATOR_187621], lime sulfur, resorcinol, or 
salicylic acid with tretinoin or other retinoids) which may affect the efficacy and safety profile of the investigational product within 2 weeks prior to study entry. 
11) Subjects who have received radiation therapy and/or anti-neoplastic agents within 3 months 
prior to screening/baseline. 
12) Subjects who have used for less than (<) 3 months prior to screening/baseline estrogens or oral 
contraceptives; use of such therapy must remain constant throughout the study. 
13) Subjects who have used any of the following procedures on the face within 1 month prior to 
screening/baseline or use during the study: 
a) cryodestruction or chemodestruction,  
b) dermabrasion,  
c) photodynamic therapy,  
d) acne surgery,  
e) intralesional steroids, or  
f) X-ray therapy.  
14) Subjects who have used any of the following treatments within 1 month prior to 
screening/baseline or during the study: 
a) androgen receptor blockers (e.g., spi[INVESTIGATOR_8407], Flutamide etc.) 
b) systemic steroids,  
c) systemic antibiotics,  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 18 of 88 d) systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-month 
washout),   
e) systemic anti-inflammatory agents. If Subject uses a systemic anti-inflammatory product 
during the study, the Principal Investigator [INVESTIGATOR_531937], 
f) have taken any drugs that lower the immune system. 
g) topi[INVESTIGATOR_285896] 
 
15) Subjects who have used any of the following treatments within 2 weeks prior to 
screening/baseline or during the study:  
a)    topi[INVESTIGATOR_8826],  
b) topi[INVESTIGATOR_22775],  
c) topi[INVESTIGATOR_531938]-the-counter preparations 
d) topi[INVESTIGATOR_900]-inflammatory agents 
e) topi[INVESTIGATOR_8163] 
f) abradants,  
g) peels containing glycolic or other acids,  
h) washes or soaps, containing glycolic acid,  
i) Alpha-hydroxy acids,  
j) sulfacetamide sodium,  
k) non-mild facial cleansers, moisturizers that contained retinol 
l) topi[INVESTIGATOR_531939] 
m) wax depi[INVESTIGATOR_531940] 
n) Use of tanning booths 
o) The application of alcohol-based toners or any product with high concentrations of 
alcohol, astringents, medicated topi[INVESTIGATOR_12469] (prescription and OTC products including those with spi[INVESTIGATOR_531941]).  or medicated make-up, medicated or harsh soaps, medicated cleansers, and cosmetics that make subject skin dry to the face (products that have a strong drying effect, particularly preparations containing sulfur, resorcinol, or salicylic acid with tretinoin or other retinoids).  
16) Subjects who have on-going malignancies requiring systemic treatment or who have any 
malignancy of the skin of the facial area. 
17) Subjects with active facial sunburn or peeling from sunburn. 
18) Subjects who engage in activities that involve excessive or prolonged exposure to sunlight or 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 19 of 88 weather extremes, such as wind or cold.  Exposure to excessive UV radiation within 1 week 
prior to screening/baseline. 
19) Subjects who use a sauna within 48 hours prior to screening/baseline. 
20) Subjects who have unstable medical disorders that are clinically significant or have life-
threatening diseases, or other medical condition (i.e., chronic infectious disease, system disorder, organ disorder, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, renal disease, severe psychiatric condition, etc.) that, in the Investigator's opi[INVESTIGATOR_1649], would place the study Subject at undue risk by [CONTACT_531990]. 
21) Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use 
drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates) within one year prior to screening. 
22) Subjects, who in the opi[INVESTIGATOR_689], would be non-compliant with the requirements 
of the study protocol.  
23) Subjects who are unable or unwilling to give informed consent.  
24) Subjects who are illiterate.  
25) Subjects who have participated in an investigational drug study (i.e., Subjects have been treated 
with an investigational drug) within 30 days prior to screening/baseline or where sufficient washout period has not been achieved; whichever time period is longer. Subjects who are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion. 
26) Subjects who have been previously enrolled in this study. 
27) Subjects who live in the same household with subjects who are participating or have been 
previously enrolled in this study. 
28) The subject is a member of the investigational study staff or a family member of the 
investigational study staff. 
29)   Subject having symptoms* of Coronavirus Disease 2019 (COVID-19) within the 10 days 
prior to screening/baseline/visit [ADDRESS_690678] with someone with suspected or confirmed Severe Acute Respi[INVESTIGATOR_7531] 2 (SARS-CoV-2) infection within 
10 days prior to screening/baseline/visit 1 or who are at high risk of SARS-CoV-2 infection, 
defined as adults whose locations or circumstances put them at appreciable risk of acquiring  SARS-CoV-2 infections. 
*Stuffy or runny nose, sore throat, shortness of breath (difficulty breathing), cough, low 
energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or 
feverish, vomiting, diarrhea, loss of sense of taste and smell. 
Number of Subjects:    
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 20 of 88 Approximately 807 subjects will be enrolled into the study in a 1:1:1 ratio, to obtain 765 subjects 
in the mITT (255:255:[ADDRESS_690679]: Reference: Placebo) and 627 in the PP subjects (209:209:[ADDRESS_690680]: Reference: Placebo) to the following study arms: 
x TRIFAROTENE CREAM, 0.005% (Teva Pharmaceuticals, Inc.) 
x AKLIEF® (TRIFAROTENE 0.005% CREAM) (GALDERMA 
LABORATORIES, L.P., [LOCATION_003]) 
x Vehicle cream (Teva Pharmaceuticals, Inc.)  
Criteria for Evaluation:   
Primary Endpoints: 
1) Mean percent change from screening/baseline to week 12 in the inflammatory 
(papules and pustules) lesion counts and; 
2) Mean percent change from screening/baseline to week 12 in the non-
inflammatory (open and closed comedones) lesion counts.  
* Counts of nodules and cysts will be reported separately and not included in the inflammatory or non-inflammatory lesion counts.  
Measures:   
a) At each visit, beginning at Visit 1, an Investigator will assess the overall status of the 
Subject’s facial acne vulgaris using the Investigator’s Global Assessment (IGA) and the inflammatory lesion counts 
b) Proportion of patients with a clinical response of “Clinical Success” using the 
Investigator’s Global Assessment (IGA) at Week 12. Success should be defined as an IGA score that is at least 2 grades less than the baseline assessment. Failure should be defined as an IGA score that is the same, higher or one grade lower than the baseline assessment. 
c) Local irritation reactions (Application site  reactions) such as erythema, dryness, 
burning/stinging, erosion, edema, pain and itching will be recorded at each visit to allow a comparison between treatment groups.  
 
Statistical Methods:    
Analysis of Primary Endpoint 
The evaluation of the primary endpoint will be based on the mean percent change from 
screening/baseline to week 12 in the inflammatory (papules and pustules) lesion counts and in the non-inflammatory (open and closed comedones) lesion counts. 
Demonstration of Bioequivalence 
Bioequivalence will be established if the 90% confidence intervals of the test/reference ratio of 
the mean percent change from screening/baseline to week 12 in the inflammatory (papules and 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 21 of 88 pustules) lesion counts and in the non-inflammatory (comedones) lesion counts are contained 
within [0.80, 1.25] using the per protocol (PP) population.  
Demonstration of Superiority 
The test product and RLD will be compared to placebo group to test statistical superiority at 
p<0.05 (two-sided test) with regard to: 
1) mean percent change from screening/baseline to week 12 in the inflammatory lesion 
counts and 
 2) mean percent change from screening/baseline to week 12 in the non-inflammatory 
lesion counts,  
both using the modified intent-to-treat (mITT) study population and Last Observation Carried 
Forward (LOCF).  
x An active treatment will be considered to be superior to the placebo if the difference in 
the means for the two treatment groups are statistically significant (p<0.05) and the active 
treatment’s mean percent reduction from screening/baseline is greater than that for placebo . 
x Analysis of local irritation reacti ons (application site reactions). 
x A descriptive analysis comparing the local irritation reactions (application site 
reactions)  for each treatment group will be conducted to ensure that the test product is 
similar to the reference product with regard to the expected and unexpected application site reactions. 
x Analysis of IGA scores:  
o Descriptive statistics using categorical methods to compare IGA Scores between 
each treatment group will be conducted and presented. No inferential analyses are planned.  
x Summary of Subjects who terminate prematurely. 
o Reasons for premature termination will be summarized by [CONTACT_1570]. 
x Concomitant medication. 
o The start and stop calendar date (e.g., mm/dd/yyyy) and study day (e.g., Day X) 
of concomitant medication used prior to and during the study will be provided in the data set in addition to the reason for the medication use. It should clearly be noted whether the medication was used prior to screening/baseline visit, during the study, or both. 
 Safety Analyses Safety analyses will be conducted on the safety population. Safety Incidence of all adverse 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 22 of 88 events reported during the study will be summarized using the MedDRA dictionary by [CONTACT_6490], body system, severity and relationship to study drug. 
The report of AEs will include relatedness to treatment, date of onset, description of the AE, 
severity, action taken, outcome and date of resolution. Formal statistical evaluation(s) of the comparability of the two active treatment groups will be conducted with regard to the frequency and severity of any AE that occurs in at least 5% of the subjects in either active treatment group.  
Application site reactions such as erythema, dryness, burning/stinging, erosion, edema, pain and 
itching will be summarized for the safety population by [CONTACT_531991].  
 
  
  
 
 
Final Version 2.0  Protocol: TRIF-[ADDRESS_690681], a pi[INVESTIGATOR_531942] a hair follicle lined with keratinocytes, a sebaceous gland, and a hair. The sebaceous gland produces a substance called sebum. Although sebum normally empties onto the skin’s surface through the openings of the follicles, the follicles may become plugged with hair, sebum and keratinocytes, resulting in comedones. Bacteria normally found on the skin may grow in the comedones, resulting in inflammation. Therefore, acne vulgaris is a multi-factorial disease, caused by [CONTACT_531992], bacterial growth, keratinization abnormalities, and immune reactivity. 
Acne is clinically characterized by [CONTACT_531993] (non-
inflammatory lesions), papules and pustules (inflammatory lesions) and nodulo-cystic lesions. The highest concentration of lesions is often found on the face, shoulders, upper back, and chest. Although acne vulgaris is most common in adolescents and young adults, it can continue to occur in adults older than [ADDRESS_690682] mode of action of trifarotene is unknown, current evidence suggests that topi[INVESTIGATOR_531943]
2. Additionally, trifarotene stimulates mitotic activity and increased turnover of follicular 
epi[INVESTIGATOR_531944].  
AKLIEF® (trifarotene) cream, for topi[INVESTIGATOR_531945] [ADDRESS_690683] for the safe and effective topi[INVESTIGATOR_531946]3, 4,5. Teva 
Pharmaceuticals, Inc. has developed a generic formulation of trifarotene 0.005% cream. The current study is designed to evaluate the safety and efficacy of this new generic formulation
6. /g4
Acne is estimated to affect 9.4% of the global population. There is no mortality associated with acne, but there is often significant physical and psychological morbidity, such as permanent scarring, poor self-image, depression, and anxiety. 
2 STUDY OBJECTIVES 
The objectives of this study are as follows: 
x To evaluate the therapeutic equivalence of TRIFAROTENE CREAM, 0.005% (Teva 
Pharmaceuticals, Inc.) and the Reference Listed Product, AKLIEF® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., [LOCATION_003]) in the treatment of acne vulgaris. 
x To demonstrate the superiority of the efficacy of the test and reference products over that 
of the placebo control in the treatment of acne vulgaris.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690684], Reference and Placebo treatments in patients with acne 
vulgaris.  
3 STUDY OVERVIEW 
Approximately 807 subjects will be assigned in a 1:1:[ADDRESS_690685], 
TRIFAROTENE 0.005% CREAM, the reference product, AKLIEF® (TRIFAROTENE 0.005% CREAM, and placebo (vehicle cream of the test product) in this multiple-center, double-blind, randomized, three-arm, placebo controlled, parallel-design study.  
The duration of each Subject’s participation in the study will be 84 days. Scheduled study visits 
will include:  
x Visit 1 (Day 0) Screening/Baseline   
x Visit 2 (First Interim Visit, Day 28) 
x Visit 3 (Second Interim Visit, Day 56) 
x Visit 4 (End of Treatment/Early Discontinuation Visit, Day 84). 
 A window period of ± 4 days will be considered acceptable for each scheduled visit following 
the screening/baseline visit. 
 At Visit 1, an informed consent/assent will be obtained from the potential study Subject prior to 
any study procedures taking place. After the Subject has been consented/assented, the Subject’s medical history will then be documented, including the Subject’s concomitant medications. A urine pregnancy test with a sensitivity to at least 25 mIU/ml hCG will be performed for female subjects of childbearing potential. A negative result of this test should be obtained.  
If necessary, subjects will be allowed to conduct screening procedures on two separate days in 
order to allow for enough time to complete the adequate washout period required for any concomitant therapy or other reasons. Subjects should sign ICF (prior to the start of any study procedures), complete washout, and return to the clinic to conduct the remainder of the screening/baseline procedures. 
The Subject will undergo a physical examination, including the recording of vital signs and 
COVID-19 symptom (such as stuffy or runny nose, sore throat, shortness of breath (difficulty breathing), cough, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish (temperature check), vomiting, diarrhea, loss of sense of taste and smell) screening. The Subject will be reviewed against the inclusion/exclusion criteria and a screening/baseline acne grade will be assigned to the Subject using the Investigator’s Global Assessment (IGA) and a screening/baseline lesion count will be performed.  
The Subject will be evaluated for signs and symptoms of local irritation. Blinded Investigational 
Medicinal Product (IMP) will be dispensed by [CONTACT_531994]. Eligible subjects will be assigned to one of the 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690686] diaries. The Independent Dispenser will not be involved in the assessments/evaluations of acne lesion counts, Investigator’s Global Assessment (IGA), evaluation of signs and symptoms of local irritation and safety assessments.  
The Subject will also be instructed not to open the study medication pump while at the study site.  
The application of Investigational Medicinal Products will be performed by [CONTACT_531995]. Subjects will be instructed to apply enough study investigational drug to lightly cover the entire 
affected areas of the face for [ADDRESS_690687]’s face has been washed with a non-medicated cleanser provided by [CONTACT_1034], and gently patted dry. The subjects should wait 20 to 30 minutes before applying the 
study medication to allow the skin to be completely dry in order to minimize possible irritation. 
For the purposes of this study, the face is considered to start at the hairline and end at the jaw line and excludes the eyes, the lips/mouth, angles/corners of the nose, open wounds and all mucous membranes.  
The subject will be instructed to wash their hands before and after application of study drug.  Subjects will be required to use diaries to document the date and time of study treatments, any 
missed treatments, any concomitant medication and the occurrence of all adverse events. 
The subjects will be instructed to bring their used IMP and their study diaries to each study visit. Subjects will return to the study site for Visit 2, Visit [ADDRESS_690688]’s concomitant 
medications (if any), IMP compliance and any AEs will be reviewed and documented. A temperature check and COVID-19 symptom (such as stuffy or runny nose, sore throat, shortness of breath (difficulty breathing), cough, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish (temperature check), vomiting, diarrhea, loss of sense of taste and smell) screening will be performed. A urine pregnancy test with a sensitivity of at least 25 mIU/ml hCG will be performed for female s ubjects of childbearing potential. A negative 
result of this test should be obtained.  
The Subject will be evaluated for signs and symptoms of local irritation and any adverse events 
will be documented. The Subject’s facial acne will be assessed using the IGA, the Subject’s lesions will be counted, and these results will be documented.  
If the Principal Investigator [INVESTIGATOR_531947]’s condition has worsened to the degree 
that it is unsafe for the Subject to continue in the study, the Subject may be discontinued from the study as a treatment failure and the Subject may be treated using the standard care or rescue medicines if there is exacerbation of their acne. 
The subjects are instructed to bring their used IMP and their study diaries to each study visit. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690689] during each scheduled visit or the Early Discontinuation Visit. 
At every study visit, all the procedures mentioned in the Table of events (Section 4) will be 
carried out. The treatment area of enrolled subjects will be assessed using IGA and lesion count. Additionally, adverse events (AEs) will be monitored, and the treatment area will be examined to assess application site reactions. Any change in concomitant medications will be noted. 
Unscheduled Visits are allowed at any time, for any reason, if in the Principal Investigator’s 
opi[INVESTIGATOR_1649], it is warranted. If the Unscheduled Visit is due to an AE, the Principal Investigator [INVESTIGATOR_531934]. If a Subject is discontinued from the study during an Unscheduled Visit, the Unscheduled Visit will be referred to as an Early Discontinuation Visit and all procedures scheduled for the Early Discontinuation Visit will be performed. If the Unscheduled Visit is not an Early Discontinuation Visit (i.e., the Subject will continue to take part in the study), then the reason for the unscheduled visit is documented and required procedures at the discretion of Investigator considering the reason for visit will be performed, with the exception of the collection of IMP and Subject diaries from Subjects. 
For example, if the subject has an unscheduled visit that is outside of the 4 day window for 
the study, the assessments and procedures will be documented as indicated above, however if the unscheduled visits is within the 4 day window for visits 1, 2 or 3 then it would be permissible to perform the optional procedures for the unscheduled visits as well as the required procedure for the scheduled visit.  
           
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 27 of 88 4 STUDY VISIT SCHEDULE 
Visit Number Visit 1 Visit 2 Visit 3 Visit 4 Unscheduled / 
Early 
Discontinuation Visit Day Day 0 Day 28 
± 4 Day 56 
± 4 Day 84 ± [ADDRESS_690690] 
Interim Second 
Interim End of 
Treatment 
COVID-19 symptom screening  ض ض ض ض ض 
Informed Consent ض     
Inclusion / Exclusion Criteria ض     
Demographics 
(Date of birth, gender, race and ethnicit y) ض     
Medical History ض     
Physical Exam ض   ض ض as needed  
Vital Signs ض ض3 ض3 ض3 ض3 
Urine Pregnancy Test 
To be conducted for all women of child-
bearing potential1 ض ض ض ض ض 
Clinical Assessment of Acne: Investigator’s 
Global Assessment (IGA) ض ض ض ض  
ض 
Investigator’s Lesion Counts Inflammatory 
and Non-Inflammatory  ض ض ض ض  
ض 
Randomization ض     
Dispense IMP and Supplies ض ض4 ض4   
Dispense Diary 
/Instructions ض ض ض   
IMP Review and Collection 
Finished cream pumps of IMP will be 
returned 4(as necessary)  ض ض ض ضas needed  
Subject Compliance/ 
Diary Review and collection  ض ض ض ضas needed  
Evaluation of Signs/Symptoms of Local 
Irritation (Application Site Reactions ) ض ض ض ض ض 
Adverse Events Assessment2 ض ض ض ض ض 
Concomitant Medication Review  ض ض ض ض ض 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690691] 
25 mIU/ml hCG. 
2 Any AEs reported after signing Info rmed Consent should be reported. 
3 Only Temperature check at visit 2, 3, 4 and Unschedu led / Early Discontinuation as part of COVID-[ADDRESS_690692] as required.  
5 STUDY POPULATION  
5.1 Number of Subjects  
This multi-center study will be comprised of subjects presenting with a clinical diagnosis of acne 
vulgaris who meet all inclusion and none of exclusion criteria. Approximately 807 subjects will be enrolled into the study in a 1:1:1 ratio, to obtain 765 subjects in the mITT (255:255:[ADDRESS_690693]: Reference: Placebo) and 627 in the PP subjects (209:209:[ADDRESS_690694]: Reference:Placebo) to the following study arms: 
x TEST:  TRIFAROTENE CREAM, 0.005% (Teva Pharmaceuticals, Inc.) 
x REFERENCE : AKLIEF® (TRIFAROTENE 0.005% CREAM) (GALDERMA 
LABORATORIES, L.P., [LOCATION_003]) 
x PLACEBO : Vehicle cream (Teva Pharmaceuticals, Inc.) 
Note: Number of study sites (approximately 15) may vary based on the subject recruitment rate.  
 
5.1.1 Inclusion Criteria  
1) Male or non-pregnant, non-lactating female aged  12 and  40 years with a 
clinical diagnosis of acne vulgaris. 
2) Subjects who are 18 years of age or older (up to the age of 40) must have 
provided IRB/IEC approved written informed consent. Subjects [ADDRESS_690695] provided IRB/IEC approved written assent; this written assent must be accompanied by [CONTACT_2717]/IEC approved written informed consent from the Subject’s legally acceptable representative (i.e., parent or guardian). In addition, all Subjects or their legally acceptable representatives (i.e., parent or guardian) must sign a HIPAA authorization. 
3) Subjects must have  25 non-inflammatory lesions (i.e., open and closed 
comedones) AND  20 inflammatory lesions (i.e., papules and pustules) AND  2 
nodulocystic lesions (i.e., nodules and cysts), at screening/baseline on the face.  
(a)For the purposes of study treatment and evaluation, these lesions should be 
limited to the facial treatment area. All lesions will be counted, including those present on the nose. Subjects may have acne lesions on other areas of the body 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 29 of 88 which will be excluded from the count and the Investigator’s Global Assessment 
(IGA) evaluation (e.g., on the back, chest and arms). 
4) Subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 
3, or 4 as per the Investigator’s Global Assessment (IGA) (per Table 2 below) at screening/baseline.  Acne vulgaris should be stable (for at least 3 months prior to screening), with minimal variation from day to day and within each day, in the opi[INVESTIGATOR_121479]. 
Table 2: Investigator’s Global Assessment (IGA) Scale for Acne Vulgaris 
Grade  Description  
[ADDRESS_690696] clear; rare non-inflammatory lesions with no more than one small 
inflammator y lesion  
2  Mild severity; greater than Grade 1; some non-inflammatory lesions with no 
more than a few inflammatory lesions (papules/pustules only, no nodular lesions)  
3  Moderate severity; greater than Grade 2; up to many non-inflammatory lesions 
and may have some inflammatory lesions , but no more than one small nodular 
lesion  
4*  Severe; greater than Grade 3; up to many non-inflammatory lesions and 
may have some inflammatory lesions, but no more than a few nodular lesions  
* The eCRF will allow for reporting by [CONTACT_68567] 4 with treatment.  Acne vulgaris Subjects with nodulocystic acne are not to be enrolled in the study. Subjects who worsen beyond Grade 4 will be described in the safety evaluation.   
Note: Counts of nodules and cysts will be reported separately and not included in the 
inflammatory or non-inflammatory lesion counts. 
5) Subjects must be willing to refrain from using all other topi[INVESTIGATOR_531948] 12-week treatment period, other than the IMP. 
6) Female Subjects of childbearing potential (*WOCBP) must not be pregnant or 
lactating at the time of screening/baseline visit as documented by a negative urine pregnancy test. 
*Female subjects of childbearing potential (WOCBP) are defined as sexually mature women 
without prior hysterectomy, or who have had any evidence of menses in the past [ADDRESS_690697] 12 or more months are still considered to be of childbearing potential, if the amenorrhea is possibly due to other causes, 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 30 of 88 including prior chemotherapy, anti- estrogens, or ovarian suppression. Postmenopausal women 
(defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or women who have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy with surgery at least 4 weeks prior to randomization) are not considered WOCBP. Subjects who have undergone tubal ligation are NOT considered as surgically sterile. 
7) Female subjects of childbearing potential must be willing to use an acceptable 
form of birth control during the study from the day of the first dose administration to [ADDRESS_690698] administration of study drug.   
(a) For the purposes of this study the following are considered acceptable 
methods of birth control: oral or injectable contraceptives, contraceptive patches, medroxyprogesterone acetate (ex. Depo-Provera
®) with stabilized use 
for at least 3 months, vaginal contraceptive (ex. etonogestrel/ethinyl estradiol vaginal ring (ex. NuvaRing
®), contraceptive implant with etonogestrel or 
equivalent, double barrier methods (e.g. condom and spermicide), intrauterine device (IUD), true abstinence (if in line with subject’s lifestyle).  
(b) If a subject who was abstinent becomes sexually active during the study, a 2
nd 
acceptable method of birth control is to be used and documented. 
(c) Subjects on hormonal contraception must be stabilized on the same type for at 
least three months prior to enrollment in the study and must not change the method during the study. A sterile sexual partner is not considered an adequate form of birth control. 
8) Female subjects who are premenarchal, surgically sterilized (by *hysterectomy or 
bilateral oophorectomy) or postmenopausal for at least 1 year) (defined as women who have been amenorrheic for at least 12 consecutive months, without other known or suspected primary cause).  
9) All male Subjects must agree to use accepted methods of birth control with their 
partners, from the day of the first dose administration to [ADDRESS_690699]’s lifestyle.  Female partners should use an acceptable method of birth control as described in the above criteria. 
10) Subjects must be willing and able to understand and comply with the 
requirements of the protocol, including attendance at all required study visits and refraining from the use of all other topi[INVESTIGATOR_531936] 12-week treatment period. 
11) Subjects must be in good health and free from any clinically significant disease, 
including but not limited to, conditions that may interfere with the evaluation of acne vulgaris or the administration of the investigative product. 
12) Subjects who use make-up must have used the same brands/types of make-up for 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690700] agree to not change 
make-up brand/type or frequency of use throughout the study. 
 
5.1.2 Exclusion Criteria 
1) Female Subjects who are pregnant, lactating or planning to become pregnant during study 
participation.  
2) Subjects with a history of hypersensitivity or allergy to trifarotene, tretinoin, retinoids, or 
any of the study medication ingredients.  
3) Subjects with the presence of any skin condition that would interfere with the diagnosis or 
assessment of acne vulgaris (Such conditions include but are not limited to the following  on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by [CONTACT_6589], steroid or corticosteroid-induced acne, steroid folliculitis, or bacterial folliculitis, auto-immune disease, perioral dermatitis, carcinoid syndrome, mastocytosis, or  acneiform eruptions caused by [INVESTIGATOR_214465]-up and medication, facial psoriasis and facial eczema). 
4) Subjects with nodulocystic acne (> 2 nodules and cysts). [Nodules or cysts defined as; 
deep-seated in the skin (i.e., centered in the dermis or subcutis) and an inflammatory 
lesion greater than or equal to 5 mm in diameter], acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or acne vulgaris requiring systemic treatment. 
5) Subjects with excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that would 
interfere with diagnosis or assessment of acne vulgaris.  
6) Subjects with tattoos or excessive facial scarring that, in the Investigator’s opi[INVESTIGATOR_1649], may 
interfere with the evaluation of the subject’s acne. 
7) Subjects who have used within 6 months prior to screening/baseline oral retinoids (e.g., 
Accutane
®) or therapeutic vitamin A supplements of greater than 10,000 units/day 
(multivitamins are allowed).  These treatments with oral retinoids or Vitamin A supplements are prohibited during the study participation. 
8) Subjects who have used within 1 month prior to screening/baseline neuromuscular 
blocking agents or androgen receptor blockers (e.g., spi[INVESTIGATOR_8407], Flutamide etc.). 
9) Subjects who have had laser therapy, electrodessication, phototherapy and or cosmetic 
procedures (e.g., ClearLight
® BOTOX, Filler, micro needling) to the facial area within 6 
months prior to study entry. 
10) Subjects who have had facial cosmetic procedures (e.g., facials) or application of cosmetic 
products (cosmetics, makeup or facial products that have a strong drying or possible interactive effect, particularly preparations  containing spi[INVESTIGATOR_187621], lime sulfur, resorcinol, or 
salicylic acid with tretinoin or other retinoids) which may affect the efficacy and safety profile of the IMP within 2 weeks prior to study entry. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 32 of 88 11) Subjects who have received radiation therapy and/or anti-neoplastic agents within 3 
months prior to screening/baseline. 
12) Subjects who have used for less than (<) 3 months prior to screening/baseline estrogens or 
oral contraceptives; use of such therapy must remain constant throughout the study.   
13) Subjects who have used any of the following procedures on the face within 1 month prior 
to screening/baseline or use during the study: 
a. cryodestruction or chemodestruction,  
b. dermabrasion,  
c. photodynamic therapy,  
d. acne surgery,  
e. intralesional steroids, or  
f. X-ray therapy.  
14) Subjects who have used any of the following treatments within 1 month prior to 
screening/baseline or during the study: 
a. androgen receptor blockers (e.g., spi[INVESTIGATOR_8407], Flutamide etc.) 
b. systemic steroids,  
c. systemic antibiotics,  
d. systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-
month washout),  
e. systemic anti-inflammatory agents.  If S ubject uses a systemic anti-inflammatory 
product during the study, the Principal Investigator [INVESTIGATOR_531937], 
f. have taken any drugs that lower the immune system 
g. topi[INVESTIGATOR_285896] 
15) Subjects who have used any of the following treatments within 2 weeks prior to 
screening/baseline or during the study: 
a) topi[INVESTIGATOR_8826],  
b) topi[INVESTIGATOR_22775],  
c) topi[INVESTIGATOR_531938]-the-counter preparations 
d) topi[INVESTIGATOR_900]-inflammatory agents 
e) topi[INVESTIGATOR_8163] 
f) abradants,  
g) peels containing glycolic or other acids,  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 33 of 88 h) washes or soaps, containing glycolic acid,  
i) Alpha-hydroxy acids,  
j) sulfacetamide sodium,  
k) non-mild facial cleansers, moisturizers that contained retinol 
l) topi[INVESTIGATOR_531939] 
m) wax depi[INVESTIGATOR_531940] 
n) use of tanning booths 
o) application to face of alcohol-based toners, cosmetics, makeup or any product with 
high concentrations of alcohol, astringents, medicated topi[INVESTIGATOR_12469] (prescription and OTC products including those with spi[INVESTIGATOR_531949]) or medicated make-up, medicated or harsh soaps, medicated cleansers, and cosmetics that make subject skin dry to the face (products that have a strong drying effect, particularly preparations containing sulfur, resorcinol, or salicylic acid with tretinoin or other retinoids).  
16) Subjects who have on-going malignancies requiring systemic treatment or who have any 
malignancy of the skin of the facial area. 
17) Subjects with active facial sunburn or peeling from sunburn. 
18) Subjects who engage in activities that involve excessive or prolonged exposure to sunlight 
or weather extremes, such as wind or cold.  Exposure to excessive UV radiation within 1 week prior to screening/baseline. 
19) Subjects who use a sauna within 48 hours prior to screening/baseline. 
20) Subjects who have unstable medical disorders th at are clinically significant or have life-
threatening diseases, or other medical condition (i.e., chronic infectious disease, system disorder, organ disorder, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, renal disease, severe psychological conditions etc.) that, in the Investigator's opi[INVESTIGATOR_1649], would place the study Subject at undue risk by [CONTACT_531990]. 
21) Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or 
use drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates) within one year prior to screening. 
22) Subjects, who in the opi[INVESTIGATOR_689], would be non-compliant with the 
requirements of the study protocol. 
23) Subjects who are unable or unwilling to give informed consent. 
24) Subjects who are illiterate. 
25) Subjects who have participated in an investigational drug study (i.e., Subjects have been 
treated with an investigational drug) within 30 days prior to screening/baseline or where 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 34 of 88 sufficient washout period has not been achieved; whichever time period is longer.  
Subjects who are participating in non-treatment studies such as observational studies or registry studies can be considered for inclusion. 
26) Subjects who have been previously enrolled in this study. 
27) Subjects who live in the same household with subjects who are participating or have been 
previously enrolled in this study. 
28) The subject is a member of the investigational study staff or a family member of the 
investigational study staff. 
29) Subject having symptoms* of Coronavirus Disease 2019 (COVID-19) within the 10 days 
prior to screening/baseline/visit [ADDRESS_690701] with someone with suspected or confirmed Severe Acute Respi[INVESTIGATOR_7531] 2 (SARS-CoV-2) infection within 10 days prior to screening/baseline/visit 1 or who are at high risk of SARS-CoV-2 infection, defined as adults whose locations or circumstances put them at appreciable risk of acquiring SARS-CoV-2 infections. 
a) *Stuffy or runny nose, sore throat, shortness of breath (difficulty breathing), cough, low 
energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, vomiting, diarrhea, loss of sense of taste and smell. 
5.1.[ADDRESS_690702] has been at a stable dose for 30 days prior to screening/baseline visit. The use of any medication that could affect the course of acne is prohibited during the entire study period. Subjects should not apply creams, lotions, powders or any topi[INVESTIGATOR_531950]. See below Table 3: Restrictions and Prohibited Medications & also exclusion criteria.  
The following are prohibited during this study: 
1. Any topi[INVESTIGATOR_531951], other than the assigned study treatment (e.g., 
Medicated topi[INVESTIGATOR_49186], cleanser/moisturizer/sunscreen other than those provided by [CONTACT_531996]). 
2. Neuromuscular blocking agents. 
3. Androgen receptor blockers (e.g., spi[INVESTIGATOR_8407], Flutamide etc.). 
4. Systemic treatment for acne vulgaris, systemic retinoids and systemic 
steroids/corticosteroids. 
5. Systemic (e.g., oral or injectable) antibiotics known to impact on the severity of facial 
acne vulgaris, including but not limited to:  
a) tetracycline and its derivatives, erythromycin and its derivatives 
b) trimethoprim and sulfamethoxazole (Bactrim™)    
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 35 of 88 NOTE: Subjects may take systemic antibiotics not known to impact the severity of facial acne 
vulgaris (e.g., penicillin) during this study after consultation with the Medical Monitor. 
6. Systemic anti-inflammatory agents (e.g., NSAIDs) in clinically significant doses affecting 
acne vulgaris.  
7. Immunosuppressive drugs.  
8. Antipruritic, including antihistamines, within [ADDRESS_690703] used the same brands/types of make-up for a minimum period of 2 weeks prior to screening/baseline visit and must agree to not change make-up (non-comedogenic) brand/type or frequency of use throughout the study. Facial topi[INVESTIGATOR_531952] [ADDRESS_690704] with high concentrations of alcohol, astringents, medicated topi[INVESTIGATOR_12469] (prescription and OTC products including those with spi[INVESTIGATOR_531949]) or medicated make-up, medicated or harsh soaps, medicated cleansers, and cosmetics that make subject skin dry to the face (products that have a strong drying effect, particularly preparations containing sulfur, resorcinol, or salicylic acid with tretinoin or other retinoids).  
12. The use of abrasive cleansers or washes (e.g., exfoliating facial scrubs) on the face. 
13. The use of adhesive cleansing strips (e.g., Bioré
® Pore Strips) on the face. 
14. Subjects must not wear make-up to any study visits, so as not to interfere with the 
evaluations. 
15. Subjects should not use a sauna during the study. 
16. Subjects should not bathe, shower, wash or swim for at least [ADDRESS_690705] to only use a non-medicated moisturizer provided by [CONTACT_1034]. The Subjects should enter the details of use of non-medicated moisturizer (how often it has been used) in diaries.  
 
  
  
 
 
Final Version 2.0  Protocol: TRIF-2101   Page 36 of 88 Table 3: Restrictions and Prohibited Medications 
Table 3: Restrictions and Prohibited Medications  
Treatment  Restriction for entire 
study duration Minimum time interval from last dose or last occurrence until time of study visit.  
 If not YES, follow 
the restrictions 
specified in the 
followin g columns. Screening/Baseline 
Visit 1  Day 28+4 Visit 2 & 
Day 56+4 Visit 3 
Interim  Visit 4  
Day 84+4  
Topi[INVESTIGATOR_531953] 
(examples: Clindamycin, 
Erythromycin)  YES 2 weeks N/A N/A 
Topi[INVESTIGATOR_285896] 
(examples: Pi[INVESTIGATOR_031], 
Tacrolimus ) YES 1 MONTH N/A N/A 
Topi[INVESTIGATOR_11930] 
(examples: Hydrocortisone, 
Betamethasone dipropi[INVESTIGATOR_16847])   YES 2 weeks N/A N/A 
Topi[INVESTIGATOR_22775] (examples: 
Adapalene, Tretinoin ) YES 2 weeks N/A N/A 
Topi[INVESTIGATOR_900]-inflammatory 
agents (example: Diclofenac 
sodium, Ibuprofen) YES 2 weeks N/A N/A 
Others including products 
used for the topi[INVESTIGATOR_531954] (examples: azelaic 
acid, salicylic acid)  
  YES 2 weeks N/A N/A 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 37 of 88 Table 3: Restrictions and Prohibited Medications  
Treatment  Restriction for entire 
study duration Minimum time interval from last dose or last occurrence until time of study visit.  
 If not YES, follow 
the restrictions 
specified in the 
followin g columns. Screening/Baseline 
Visit 1  Day 28+4 Visit 2 & 
Day 56+4 Visit 3 
Interim  Visit 4  
Day 84+4  
Facial topi[INVESTIGATOR_49186] 
(examples: Creams, lotions, 
facial moisturizers, make-up, 
ointments, cosmetics, 
sunscreens; (non-medicated 
facial cleanser is acceptable) Within [ADDRESS_690706] 
brands/types should 
be applied throughout 
the study.  The same brands must 
be used from 2 weeks 
prior to Visit 1. Within 12 hours prior 
to the scheduled clinic 
visit. Within 12 hours prior to 
the scheduled clinic visit.               
Systemic Treatments     
Systemic antibiotics and 
corticosteroids (examples: 
Doxycycline, 
Hydrocortisone) YES  1 MONTH N/A N/A 
Systemic anti-inflammatory 
agents (examples: Aspi[INVESTIGATOR_248], 
Ibuprofen) YES  1 MONTH N/A N/A 
Systemic treatments for acne 
vulgaris (examples: 
Tetrac ycline, isotretinoin ) YES  1 MONTH N/A N/A 
Oral retinoids (example: 
ACCUTANE®) YES 6 MONTHS  N/A N/A 
Subjects who have used 
within 1 month prior to 
screening/baseline 
neuromuscular blocking 
agents or androgen receptor 
blockers (e.g., 
spi[INVESTIGATOR_8407], Flutamide 
etc.). YES 1 MONTH NA NA 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 38 of 88 Table 3: Restrictions and Prohibited Medications  
Treatment  Restriction for entire 
study duration Minimum time interval from last dose or last occurrence until time of study visit.  
 If not YES, follow 
the restrictions 
specified in the 
followin g columns. Screening/Baseline 
Visit 1  Day 28+4 Visit 2 & 
Day 56+4 Visit 3 
Interim  Visit 4  
Day 84+4  
Other     
Phototherapy (examples: 
laser, light-source (e.g., 
intense pulsed light, 
photodynamic therapy) or 
other energy-based therapy), 
electrodessication YES  6 MONTHS N/A N/A 
Any dermatologic or surgical 
procedure on face YES  1 MONTH N/A N/A 
Exposure to excessive UV 
radiation YES 1 week N/A N/A 
Monoamine oxidase (MAO) 
inhibitors, barbiturates, 
opi[INVESTIGATOR_858], sedatives, systemic 
anesthetics.  YES 1 YEAR N/A N/A 
Application of any medicated 
or harsh soaps on face. The 
only allowable facial soaps 
should be unscented and no 
additives. YES 2 WEEKS N/A N/A 
The use of antipruritic, 
including antihistamines, 
within 24 hours of the study 
visit Within 24 hours prior 
to visit Within 24 hours prior to 
visit Within 24 hours prior 
to visit Within 24 hours prior to 
visit 
The use of abrasive cleaners 
or washes (e.g., exfoliating 
facial scrubs ) on the face YES 2 weeks N/A N/A 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 39 of 88 Table 3: Restrictions and Prohibited Medications  
Treatment  Restriction for entire 
study duration Minimum time interval from last dose or last occurrence until time of study visit.  
 If not YES, follow 
the restrictions 
specified in the 
followin g columns. Screening/Baseline 
Visit 1  Day 28+4 Visit 2 & 
Day 56+4 Visit 3 
Interim  Visit 4  
Day 84+4  
The use of adhesive 
cleansing strips (i.e., Bioré® 
Pore Stri ps) on the face YES 2 weeks N/A N/A 
Wax epi[INVESTIGATOR_531955] 2 weeks Since 
Screening/Baseline Since Screening/Baseline 
Cosmetic procedures (e.g., facials) 
to face and  YES 2 weeks Since 
Screening/Baseline Since Screening/Baseline 
Cosmetic product (cosmetics that 
have a strong drying effect, 
particularly preparations 
containing sulfur, resorcinol, or 
salicylic acid with tretinoin or 
other retinoids. 
 YES 2 weeks Since 
Screening/Baseline Since Screening/Baseline 
The application of alcohol-based 
toners, makeup or any product 
with high concentrations of 
alcohol, astringents, medicated 
topi[INVESTIGATOR_12469] (prescription 
and OTC products including those 
with spi[INVESTIGATOR_531949]) or medicated 
make-up, medicated or harsh 
soaps, medicated cleansers, and 
cosmetics that make subject skin 
dry to the face (products that have 
a strong drying YES 2 weeks Since 
Screening/Baseline Since Screening/Baseline 
Radiation therapy and/or 
anti-neo plastic a gents YES 3 MONTHS Since 
Screenin g/Baseline Since Screening/Baseline 
 
  
  
 
 
Final Version 2.0  Protocol: TRIF-2101   Page 40 of 88  
Acceptable Medications for use throughout the study : 
1. Contraceptives – Acceptable methods of birth control as listed in the Inclusion Criteria.  
Subjects on hormonal contraception must be s tabilized on the same type for at least [ADDRESS_690707] not change the method during the study. 
2. Acetaminophen - Acetaminophen will be allowed during the study with a maximum dose 
of 1g (i.e., 1000 mg) twice daily and for a maximum of 3 consecutive days. 
3. Non-medicated moisturizers (supplied by [CONTACT_3211]) or cleaning agents only, when 
necessary, as directed by [CONTACT_1697]. 
4. Oral retinoids, therapeutic vitamin A supplements of less than 10,000 units/day (multi-
vitamins are allowed). 
Subjects will be allowed to apply the study medicati on to any affected area(s) of their trunk as 
needed. No other medication will be allowed to be applied to these affected area(s).  
Subjects will be questioned about all prescription and over the counter (OTC) concomitant 
medication use (including vitamins, nutritional supplements, herbal supplements, all topi[INVESTIGATOR_49186]) at each study visit. All concomitant medications will be recorded in the Subject's source documents. Any Subject who violates the listed restrictions may be dropped from continued participation in the study by [CONTACT_531997].  
5.1.4 Precautions  
The following precautions are to be taken during this study:  
1. To minimize exposure to sunlight and or extreme weather conditions, a wide-brimmed hat 
or other protective clothing should be worn.  The non-comedogenic sunscreen with a SPF 15 rating or higher provided by [CONTACT_287793]. 
2. The IMP should not be applied to cuts, open wounds, abrasions, sunburn or eczematous 
skin. 
3. The IMP should not be applied to the eyes, the mouth/lips, the angles/corners of the nose 
or any mucous membranes. 
4. Subjects should wash their hands before and after application of the product. 
If a reaction suggesting sensitivity or chemical irritation occurs, the Principal Investigator [INVESTIGATOR_531956]’s condition as soon as possible (i.e., during an Unscheduled Visit) and determine whether treatment should be discontinued. If a Subject is discontinued from the study during an Unscheduled Visit, the Unscheduled Visit will be referred to as an Early Discontinuation Visit and all procedures scheduled for the Early Discontinuation Visit will be performed. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690708] whose health or well-being may be threatened by [CONTACT_94597], or who may be experiencing unmanageable factors that may interfere with the study procedures and/or the interpretation of study results.  Such Subjects should be withdrawn from the study rather than continued under a modified regimen. The reason for withdrawal or discontinuation from the study will be documented appropriately. 
In addition, investigational product will be stopped, and Subjects will be discontinued from the 
study for any of the following reasons:  
a. If the Subject withdraws his or her consent/assent for any reason. 
b. Subjects who are discontinued early from the study due to lack of treatment effect 
should be included in the PP population as treatment failures, using Last Observation Carried Forward (LOCF). 
c. If the Subject’s acne condition has worsened beyond grade [ADDRESS_690709]’s drug code is unblinded. 
g. If an adverse event occurs for which the Subject desires to discontinue treatment or the 
Principal Investigator [INVESTIGATOR_94569]’s best interest to be discontinued. 
h. If there is a significant protocol deviation if it affects the safety or well-being of the 
subject. 
i. If subject misses three or more consecutive doses of IMP. 
j. If a concomitant therapy is reported or required which is liable to interfere with the 
results of the study. 
k. If the Subject is lost to follow-up.  
l. If the Subject becomes pregnant. 
m. If the Subject becomes a prisoner or becomes involuntarily incarcerated.  
n. Any other reason that may affect the outcome of the study or the safety of Subjects; or 
o. Termination of the study by [CONTACT_1034]. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690710] data integrity. Subjects with protocol deviations are not required to be discontinued from the study unless, in the Investigator’s opi[INVESTIGATOR_1649], continuation in the study could be harmful to the health or wellbeing of the subject. Subjects that have a major protocol deviation which effects their safety or wellbeing should be discontinued.  
The reasons for a Subject discontinuation will be documented. If a Subject is discontinued from 
the study for any reason, Early Discontinuation Visit procedures will be completed and any outstanding data and study drug should be collected if possible. In addition to the reason for discontinuation the collected data will include the initiation of any rescue medicines, the date of removal and will be documented in the electronic Case Report Form (eCRF). The Sponsor will be notified. 
Before a subject is considered to be lost to follow-up, the Principal Investigator [INVESTIGATOR_531957] a certified follow-up letter. 
In the event that a subject discontinues from the study at any time due to an adverse event (AE), 
the reason for discontinuation, the nature of the event and its clinical course must be fully documented (see also reporting AEs and SAES, Section 11.0). For such a subject, the Principal Investigator [INVESTIGATOR_531958], becomes clinically insignificant, is stabilized or the subject is lost to follow-up. In case of any serious adverse events, procedures for reporting must be followed.  
6 SAFETY AND TOLERABILITY EVALUATIONS 
Safety will be assessed based on following:  
x Vital signs evaluation, 
x Physical Examination  
x COVID-19 symptoms screening,  
x Reported Adverse Events and Serious Adverse Events,  
x Assessment of local facial tolerability-rating of erythema, dryness, stinging/burning, 
erosion, edema, pain and itching for each treatment group will be recorded and reported, 
x Lack of effect of investigative products on indication.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690711]’s current and past medical 
conditions. Significant medical history should include, but not be limited to, evidence of hypertension, lipid disorders, obesity
1, heart attack, stroke, congestive heart failure, kidney 
disease, auto immune disease and gestational diabetes. Significant surgical history should include, but not be limited to, removal of blockage from an artery and gallbladder removal. 
Concomitant medications and treatments, including the use of sunscreen, OTC products, herbal 
products, topi[INVESTIGATOR_531959], (non-drug treatments/therapi[INVESTIGATOR_014]) etc., in addition to the reason for the medication use, will be assessed at screening/baseline and at each subsequent study visit. The start and stop calendar date (e.g., mm/dd/yyyy) and study day (e.g., Day X) and name [CONTACT_532040]. It should clearly be noted whether the medication was used prior to screening/baseline visit, during the study, or both. 
Additional assessment to assess subject safety, such as physical examinations, measurements of 
vital signs are described below and included in the Schedule of Assessments for periodic measurements.  
All female subjects of childbearing potential will undergo a urine pregnancy test with a 
sensitivity of at least 25 mIU/ml hCG at Visit 1, Visit 2, Visit [ADDRESS_690712] 1 year. 
 
6.1.1 Physical Examination 
A brief physical examination will be performed at screening/baseline, Visit 4 End of 
Treatment/Early Discontinuation and during an UNS visit where applicable. The physical examination will include, at a minimum, examination of the Subject’s general appearance, skin, HEENT (head, eyes, ears, nose and throat), heart, lungs, musculoskeletal system, neurological system, lymph nodes, abdomen and extremities. It is recommended the Subject’s body weight should be measured while the Subject is lightly clothed (e.g., no coat or shoes). 
The investigator, sub-investigator or appropriately delegated designee (Physician’s Assistant, 
Advanced Registered Nurse Practitioner, and Registered Nurse as per local regulations) will perform a brief physical examination, prior to the Subject starting study drug.  A delegation log will be maintained at site.  
 
 
1 Obesity = BMI 30 (as defined by [CONTACT_94605], Appendix III) 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690713] has rested in a seated position for about 5 minutes.  
Blood pressure (millimeters of mercury [mmHg]) and heart rate (beats per minute [bpm]) will be 
measured during the physical examination after [ADDRESS_690714] in sitting position. Blood pressure and heart rate will be obtained preferably usi ng the same arm and same equipment each time. If 
one arm has higher blood pressure than the other, that arm should be used for further blood pressure measurements (all further blood pressure measurements should be done in the same arm). 
Body temperature will be measured using FDA approved tympanic or infrared thermometer with 
digital display and recorded in the eCRF in degree Celsius (°C). Preferably the same method will be used each time. 
Vital signs, including blood pressure, pulse rate, respi[INVESTIGATOR_531960] 1. Vital signs will be measured after the Subject has rested in a seated position for at least 5 minutes. Additionally, temperature will also be documented at Visit 2, 3, 4 and Unscheduled / Early Discontinuation as part of COVID-[ADDRESS_690715] 25 mIU/ml hCG during Visit [ADDRESS_690716] been surgically sterilized (by *hysterectomy or bilateral oophorectomy) or have been postmenopausal for at least [ADDRESS_690717].  
*Female subjects of childbearing potential (WOCBP) are defined as sexually mature women 
without prior hysterectomy, or who have had any evidence of menses in the past [ADDRESS_690718] 12 or more months are still considered to be of childbearing potential, if the amenorrhea is possibly due to other causes, including prior chemotherapy, anti- estrogens, or ovarian suppression. Postmenopausal women (defined as women who have been amenorrheic for at least 12 consecutive months, in the appropriate age group, without other known or suspected primary cause) or women who have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy with surgery at least 4 weeks prior to randomization) are not considered WOCBP. Subjects who have undergone tubal ligation are NOT considered as surgically sterile. 
Women of childbearing potential, in addition to having a negative urine pregnancy test, must be 
willing to use an acceptable form of birth control during the study from the day of the first dose 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690719] administration of study drug.  
Female subjects who are premenarchal, surgically sterilized (by [CONTACT_531998]) or postmenopausal for at least [ADDRESS_690720] and are not required to use an acceptable form of birth control. 
Full hysterectomy or bilateral oophorectomy are considered surgically sterile. Tubal ligation is 
not considered equivalent to female sterilization. 
For the purpose of this study the following are considered acceptable methods of birth control: 
oral or injectable contraceptives, contraceptive patches, medroxyprogesterone acetate (ex. Depo-Provera®) with stabilized use for at least 3 months, vaginal contraceptive (ex. etonogestrel/ethinyl estradiol vaginal ring (ex. NuvaRing®), contraceptive implant with etonogestrel or equivalent, double barrier methods (e.g., condom and spermicide), IUD, abstinence. If a subject who was abstinent becomes sexually active during the study, a 2nd acceptable method of birth control should be used and documented.  
A sterile sexual partner is NOT considered an adequate form of birth control. Subjects on 
hormonal contraception must be stabilized on the same type for at least three months prior to enrollment in the study and must not change the method during the study.   
 
6.2 Concomitant Medications 
Concomitant medications and therapeutic treatments, including the use of sunscreen, OTC 
products, herbal products, topi[INVESTIGATOR_531959], dietary supplements and any current non-drug treatments/therapi[INVESTIGATOR_531961]/baseline visit and at each subsequent study visit. The start and stop calendar date (e.g., dd/mmm/yyyy and study day (e.g., Day X) of concomitant medication use during the study should be provided in the data set in addition to the reason for the medication or treatment use. It should clearly be noted whether the medication was used prior to screening/baseline visit, during the study, or both. 
A record of concomitant medications taken by [CONTACT_94600], 
if known, with the corresponding indication. The medications to be recorded will include prescription and over-the-counter (OTC) medications and dietary supplements. Any therapeutic treatments during the trial should also be recorded. All medications taken on a regular basis, including acetaminophen, should be recorded. 
 
6.3 Evaluation of Signs/Symptoms of Local Irritation/Application Site 
Reactions 
At each study visit, beginning at Visit 1, Subjects will be evaluated for any signs and symptoms 
of local irritation such as erythema, dryness, burning/stinging, erosion, edema, pain and itching. The scores for each visit will be documented to allow a comparison between treatment groups.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 46 of 88 The following scale will be used for the signs and symptoms of local irritation:  
 
Score Assessment Description 
[ADDRESS_690721] presence 
3 Severe Marked, intense 
Subjects with a screening/baseline irritation score of 3 (severe, marked/intense) will not be 
enrolled. 
Signs and symptoms of local irritation are to be recorded only as AEs if they significantly 
worsen, require any medical intervention or result in subject discontinuation (eg. after screening/baseline, severe irritation (i.e., grade 3, described as severe or marked/intense) that requires treatment will be reported as an adverse event).  
Local irritation reactions in the treatment area are common and the Investigator may instruct 
Subjects to stop the application of treatment (“rest period”) to reduce Subject discomfort and to allow local skin reactions to subside based upon the Investigator’s clinical assessment. The Investigator may advise the subject to use the Sponsor provided moisturizer at this time. Treatment should resume as soon as the reaction subsides sufficiently to allow reapplication. The Subject should not miss the scheduled application for more than three (3) consecutive doses. The Subject should not modify or resume the treatment regimen without consultation with the Investigator. The Investigator may make this decision based upon a documented phone consultation or at an unscheduled visit. All dose modifications must be reported on the appropriate Study Medication Log & Dosing Compliance eCRF, along with Subject documenting in the subject diary. 
The treatment period should not be extended beyond [ADDRESS_690722] 28 days (or in the opi[INVESTIGATOR_689]) should be re-evaluated by [CONTACT_94602]. 
6.4 Adverse Events  
An adverse event (AE) is defined as any untoward medical occurrence (sign, symptom or 
abnormal laboratory finding) regardless of severity in a Subject or clinical-trial Subject administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. All advers e events, whether observed by [CONTACT_531999], whether related to study drug or not related to study drug, shall be documented on Subject records, together with details, i.e., date of onset, 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 47 of 88 description of the AE, the duration and intensity of each epi[INVESTIGATOR_1865], the action taken, the 
relationship to the IMP and the degree of severity, the seriousness, date of resolution and the outcome.  
All reported adverse events and serious adverse events will be recorded and reported as per 
section 11.0 Adverse Events. 
6.5 COVID-19 symptom screening 
Temperature check and COVID-19 symptom (such as Stuffy or runny nose, Sore throat, 
Shortness of breath (difficulty breathing), Cough, Low energy or tiredness, Muscle or body aches, Headache, Chills or shivering, feeling hot or feverish (temperature check), vomiting, diarrhea, loss of sense of taste and smell) screening will be done for each subject at visit 1, 2, 3, 4 and Unscheduled / Early Discontinuation visit. During the screening, if the subject found to have any one of the above said symptoms, then it will be judged by [CONTACT_532000]-related to COVID-[ADDRESS_690723] (LOTE) 
After completion of at least [ADDRESS_690724] makes the decision to withdraw or discontinue from the study, then the reason for withdrawal/discontinuation will be coded as “lack of treatment effect (LOTE).”  The subject would be included in the PP population as a treatment failure using Last Observation Carried Forward (LOCF).  
[ADDRESS_690725]’s face will be pe rformed at screening/baseline and at each 
subsequent visit.  During the dermatologic examination, evaluations to determine efficacy of treatment will be conducted, including grading of the Subject’s facial acne using the criteria outlined in the IGA and lesion counts. The IGA should be done before lesion counts. 
Preferably a single Investigator (i.e., Principal Investigator [INVESTIGATOR_54720]-Investigator) or qualified staff 
will perform evaluations of efficacy (i.e., lesion counts and IGA) for each Subject at each visit from the beginning to the end of the Subject’s participation to maintain consistency and lessen interrater variability; however, only up to two Investigators or qualified staff may perform 
evaluations of efficacy for a single Subject if necessary. All efforts should be made to have the 
same evaluator at Visit [ADDRESS_690726] of these evaluations (i.e., lesion counts and IGA). 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 48 of 88 7.1 Investigator’s Global Assessment (IGA) 
At each study visit, beginning at Visit 1, an Investigator will assess the overall status of the 
Subject’s face for acne vulgaris using the IGA. To be included in the study, subjects must have a definite clinical diagnosis of acne vulgaris of severity grade 2, 3, or 4 at screening/baseline.  
The following scale will be used for the IGA: 
 
Grade  Definition  
[ADDRESS_690727] clear; rare non-inflammatory  lesions with no more than one 
small inflammator y lesion 
2 Mild severity; greater than Grade 1; some non-inflammatory lesions 
with no 
more than a few inflammatory lesions (papules/pustules only, no 
nodular 
lesions)  
3 Moderate severity; greater than Grade 2; up to many non-
inflammatory lesions 
and may have some inflammatory lesions, but no more than one 
small nodular 
lesio n 
4* Severe; greater than Grade 3; up to many non-inflammatory lesions 
and may 
have some inflammatory lesions, but no more than a few nodular 
lesions 
* The eCRF will allow for reporting by [CONTACT_68567] 4 with treatment. Subjects with nodulocystic acne vulgaris are not to be enrolled in the study. Subjects who worsen beyond Grade 4 will be described in the safety evaluation. 
Please note that counts of nodules and cysts will be reported separately and not included in the 
inflammatory or non-inflammatory lesion counts. 
7.2 Lesion Counts 
At each study visit, beginning at Visit 1, an Investigator will assess by [CONTACT_532001] (non-inflammatory lesions), pustules and papules (inflammatory lesions) and nodulo-cystic lesions from the jaw line to the hairline. All lesions will be counted, 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 49 of 88 including those present on the nose. Counts of nodules and cysts should be reported separately 
and not included in the inflammatory or non-inflammatory lesion counts. A papule with a pustule on its apex will be counted as a pustule.  Lesions involving the eyes, lips/mouth and scalp should be excluded from the count. Identity of the evaluator will be recorded in the source and the eCRF. 
To be included in the study, subjects must have  25 non-inflammatory lesions (i.e., open and 
closed comedones) AND  20 inflammatory lesions (i.e., papules and pustules) AND  2 
nodulocystic lesions (i.e., nodules and cysts), at screening/baseline on the face.  
 
Lesion Type  Definition 
Closed Comedone Non-inflammatory lesion; whitehead, skin-colored or 
slightly inflamed “bump” in the ski n 
Open Comedone Non-inflammatory lesion: blackhead, surface of the 
plugged sebaceous follicle has a blackish appearance 
Papule Inflammatory lesion: a small (  5mm in diameter), 
solid palpable lesion, usually with inflamed elevation of the skin that does not contain pus 
Pustule Inflammatory lesion: a small (  5mm in diameter), 
inflamed skin swellin g that is filled with pus 
Nodules Large, hard bumps under the skin's surface 
Cysts Similar to a nodule, but is pus-filled, and  5mm in 
diamete r 
8 STUDY VISITS (SEE STUDY VISIT SCHEDULE) 
8.1 Visit 1: Screening and Baseline (Day 0)  
The following procedures will be performed at Visit 1:  
1. Written informed consent/assent will be obtained . Subjects who are 18 years of age or 
older (up to the age of 40) must have provided IRB/IEC approved written informed consent. Subjects [ADDRESS_690728] provided IRB/IEC approved written assent. Written assent must be accompanied by [CONTACT_2717]/IEC approved written informed consent from the Subject’s legally acceptable representative (i.e., parent or guardian). Prior to initiating screening for the study, Subjects will be given the approved ICF/informed assent form (IAF) describing the study and any risks associated with participation. The Subject will be allowed as much time as needed to read and understand the information presented in the consent/assent form. Appropriate study personnel will be available to answer any questions the Subject might have regarding the study or study-
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690729] chooses to participate in the study, he or she will be 
asked to sign and date the consent/assent form and will be provided with a copy for his or her records. Both the ICF and assent (if applicable) must be signed by [CONTACT_532002]’s legally acceptable representative (i.e., parent or guardian) before any protocol assessments can be undertaken. 
 
2. Screening /Baseline Demographics: Demographics  will be collected, including date of 
birth, gender, race and ethnicity. 
3. COVID-19 symptom screening.  
4. Medical History : A complete medical history will be obtained for the Subject’s current 
and past medical conditions. Significant medical history should include, but not be limited to, evidence of hypertension, lipid disorders, obesity*, heart attack, stroke, congestive heart failure, kidney disease, and auto immune disease and gestational diabetes. Significant surgical history should include, but not be limited to, removal of blockage from an artery and gallbladder removal. 
* Obesity = BMI 30 (as defined by [CONTACT_94605]) 
5. Vitals : Vital signs (blood pressure, pulse, respi[INVESTIGATOR_12876]) will be 
documented. Subjects must remain in a seated position for at least 5 minutes before vital signs are obtained. 
6. Physical Examination : A brief physical examination, including height (measured in 
inches) and weight (measured in pounds), will be performed. At a minimum, the physical examination will include the following: assessment of general appearance, skin, Head, Eyes, Ears, Nose and Throat (HEENT), heart, lungs, musculoskeletal system, lymph nodes, neurological systems, abdomen, and extremities. 
7. Concomitant Medications : A complete list of current and past (within the previous 6-
months) concomitant medications will be obtained for each Subject.  
8. Pregnancy Test:  A urine pregnancy test will be conducted for all females of 
childbearing potential.  
9. Clinical Assessment:    An evaluation of the patient’s acne will be performed by [CONTACT_532003]. 
10. Investigator Global Assessment : The overall status of the Subject’s facial acne vulgaris 
(from the jaw line to the hairline) will be assessed using the IGA.  
11. Lesion  Count : Lesion counts will be done by [CONTACT_532004], pustules, papules and nodulo-cystic lesions from the jaw line to the hairline. All lesions will be counted, including those present on the nose.  
 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 51 of 88 12. Application Site Reaction : Subjects will be evaluated for any signs and symptoms such 
as erythema, dryness, burning/stinging, erosion, edema, pain and itching.  
13. Inclusion/Exclusion Criteria : When the Subject has completed all screening procedures, 
compliance with the inclusion and exclusion criteria will be reviewed. After the inclusion and exclusion criteria have been confirmed, the Subject will be randomized to a treatment group. The Subject will be assigned a randomization number.  
14. Adverse Events : The occurrence of all AEs will be assessed and documented following 
procedures.  
15. Randomization:  Subjects will be randomly assigned in a treatment allocation ratio of 
1:1:[ADDRESS_690730] and Supplies : The following will be dispensed 
during Visit [ADDRESS_690731] randomization by [CONTACT_531996]:  
• The investigational product (1 pump) 
• Non-medicated cleanser  
• Sunscreen with SPF 15 or greater 
• Two packs Towels 
• A diary card to record product use from Visit [ADDRESS_690732].  
Randomized Subjects will be provided with a diary and instructed how and when to complete the 
diary. They will be told that they are to document all treatments administered, including the date and time and all treatments missed. In addition, Subjects will be instructed to document all AEs. Subjects will also be instructed to call the study site if they experience any severe intolerability (i.e., local skin reactions) to IMP. 
17. Visit 2  (Day 28 ± 4 days from the date of Visit 1): will be scheduled and the Subject will 
be instructed to bring all IMP (used, unused, and partially used) and the Subject diary with him or her to this visit. Subjects will be reminded not to use any facial topi[INVESTIGATOR_531962] 12 hours prior to the next scheduled clinic visit. 
 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 52 of 88 8.2 Visit 2: First Interim (Week 4; Day 28 ± 4 Days) 
The following procedures will be performed at Visit 2: 
1. Initial Check : Temperature check and COVID-[ADDRESS_690733] : A urine pregnancy test will be conducted for all females of 
childbearing potential.  
3. Subject Compliance : The Subject’s compliance with the study protocol, including use, 
application and compliance of IMP, will be  assessed. The Subject’s diary will be 
collected and reviewed for completion.  
4. Investigational Medicinal Product : The Subject’s IMP dispensed at Visit 1 will be 
returned to the Independent Dispenser for review and re-dispensed if IMP remains.  
5. Concomitant Medication : The use of concomitant medications since the previous study 
visit will be documented and assessed for each Subject.  
6. Adverse Events : The occurrence of all AEs will be assessed and documented following 
procedures.  
7. Investigator Global Assessment : The overall status of the Subject’s facial acne vulgaris 
(from the jaw line to the hairline) will be assessed using the IGA by [CONTACT_532005].  
8. Lesion Count:  Lesion counts will be done by [CONTACT_532004], pustules, papules and nodulo-cystic lesions from the jaw line to the hairline. All lesions will be counted, including those present on the nose.  
9. Application Site Reaction : Subjects will be evaluated for any signs and symptoms such 
as erythema, dryness, burning/stinging, erosion, edema, pain and itching.  
10. Investigational Medicinal Product and Supplies:  
The following will be dispensed during Visit 2:  
x The investigational product (1 pump) (new pump assigned through the 
randomization system and or pump from screening/baseline visit re-dispensed if 
sufficient IMP remains) 
x One pack of Towels  
x Cleanser (as required) 
x A diary card will be dispensed to record product use from Visit [ADDRESS_690734] to use a non-
medicated, noncomedogenic moisturizer provided by [CONTACT_1034]. If the moisturizer was not dispensed at Visit 1, one bottle of non-medicated moisturizing cream or lotion may be dispensed, only if necessary. It is not anticipated that Subjects will require additional supplies during this visit; additional supplies will be dispensed if required. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690735], including the procedure for 
application of the IMP.  
12. Visit 3 (Day 56 ± 4 days from the date of Visit 1): will be scheduled and the Subject will 
be instructed to bring all IMP (used, unused, and partially used) and the Subject diary with him or her to this visit. Subjects will be reminded not to use any facial topi[INVESTIGATOR_531962] 12 hours prior to the next scheduled clinic visit. 
8.3 Visit 3: Second Interim (Week 8; Day 56 ± 4 Days)  
The following procedures will be performed at Visit 3: 
 
1. Initial Check : Temperature check and COVID-[ADDRESS_690736]:  A urine pregnancy test will be conducted for all females of 
childbearing potential.  
3. Subject Compliance : The Subject’s compliance with the study protocol, including use, 
application and compliance of IMP, will be  assessed. The Subject’s diary will be 
collected and reviewed for completion.  
4. Investigational Medicinal Product : The Subject’s IMP dispensed at the previous 
visit(s) will be returned to the Independent Dispenser for review, collection and or re-dispensed if IMP remains.  
5. Concomitant Medication : The use of concomitant medications since the previous study 
visit will be documented and assessed for each Subject. 
6. Adverse Events : The occurrence of all AEs will be assessed and documented following 
procedures.  
7. Investigator Global Assessment:  The overall status of the Subject’s facial acne vulgaris 
(from the jaw line to the hairline) will be assessed using the IGA.  
8. Lesion Count : Lesion counts will be done by [CONTACT_532004], pustules, papules and nodulo-cystic lesions from the jaw line to the 
hairline. All lesions will be counted, including those present on the nose.  
9. Application Site Reaction : Subjects will be evaluated for any signs and symptoms of 
signs and symptoms of facial irritation such as erythema, dryness, burning/stinging, erosion, edema, pain and itching.  
10. Investigational Medicinal Product: 
The following will be dispensed during Visit 3:  
x The investigational product (1 pump) (new pump assigned through the 
randomization system if required and or pump dispensed at Visit 2 re-
dispensed if IMP still remains). 
x One pack of Towels 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 54 of 88 x Cleanser (as required) 
x A diary card will be dispensed to record product use from Visit [ADDRESS_690737] to use a non-
medicated, noncomedogenic moisturizer provided by [CONTACT_1034], only if necessary. If the moisturizer was not dispensed at the previous study visits, one bottle of non-medicated moisturizing cream or lotion may be dispensed. It is not anticipated that Subjects will require additional supplies during this visit; additional supplies will be dispensed if required. 
11. Study instructions will be reviewed with the Subject, including the procedure for 
application of the IMP.  
12. Visit 4  (Day 84 ± 4 days from the date of Visit 1): will be scheduled and the Subject will 
be instructed to bring all IMP (used, unused, and partially used) and the Subject diary with him or her to this visit. Subjects will be reminded not to use any facial topi[INVESTIGATOR_531962] 12 hours prior to the next scheduled clinic visit. 
8.4 Visit 4: End of Treatment (Week 12; Day 84 ± 4 Days)  
The following procedures will be performed at Visit 4: 
1. Initial Check : Temperature check and COVID-[ADDRESS_690738]:  A urine pregnancy test will be conducted for all females of 
childbearing potential.  
3. Subject Compliance : The Subject’s compliance with the study protocol, including use, 
application and compliance of IMP, will be  assessed. The Subject’s diary will be 
collected and reviewed for completion.  
4. Investigational Medicinal Product : The Subject’s IMP dispensed at the previous 
visit(s) will be returned to the Independent Dispenser.  
5. Concomitant Medication : The use of concomitant medications since the previous study 
visit will be documented and assessed for each Subject.  
6. Adverse Events : The occurrence of all AEs will be assessed and documented following 
procedures. 
7. Investigator Global Assessment:  The overall status of the Subject’s facial acne vulgaris 
(from the jaw line to the hairline) will be assessed using the IGA.  
8. Lesion Count:  Lesion counts will be done by [CONTACT_532004], pustules, papules and nodulo-cystic lesions from the jaw line to the hairline. All lesions will be counted, including those present on the nose.  
9. Physical Examination : A brief physical examination, including height (measured in 
inches) and weight (measured in pounds), will be performed. At a minimum, the physical examination will include the following: assessment of general appearance, skin, Head, 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 55 of 88 Eyes, Ears, Nose and Throat (HEENT), heart, lungs, musculoskeletal system, lymph 
nodes, neurological systems, abdomen, and extremities. 
10. Application Site Reaction:  Subjects will be evaluated for any signs and symptoms of 
erythema, dryness, burning/stinging, erosion, edema, pain and itching.  
8.5 Unscheduled Visits and Early Discontinuation Visit 
An Unscheduled Visit is allowed at any time, for any reason, if in the Principal Investigator’s 
opi[INVESTIGATOR_1649], it is warranted. If the Unscheduled Visit is due to an AE, the Principal Investigator [INVESTIGATOR_531934].  
If a Subject is discontinued from the study during an Unscheduled Visit, the Unscheduled Visit 
will be referred to as an Early Discontinuation Visit and all procedures scheduled for the Early 
Discontinuation Visit will be performed. If the Unscheduled Visit is not an Early Discontinuation Visit (i.e., the Subject will continue to take part in the study), then the reason for the unscheduled visit is documented and required procedures at the discretion of Investigator considering the reason for visit will be performed apart from the collection of IMP and Subject diaries from Subjects.   
If the Subject’s condition has worsened to the degree that it is unsafe for the Subject to continue 
in the study, the Subject may be discontinued from the study as treatment failure and a standard 
of care treatment may be advised at the Principal Investigator’s discretion. 
   
8.6 Premature Termination of Study/Study Site 
The Sponsor reserves the right to discontinue the study at any time. The reasons will be 
discussed with the Investigator. A study site may also be discontinued by [CONTACT_532006]. 
The Sponsor may terminate this study in one particular or several study center(s) for one (or 
other) of the following reasons: 
a. Non-compliance with GCP and/or regulatory requirements 
b. Centre cannot recruit an adequate number of subjects 
c. False data captured in the eCRF due to carelessness or deliberately 
d. Inadequate co-operation with the Sponsor or its representatives 
e. The Investigator requests closure of his/her study center. 
If the study is prematurely terminated in one or more study centers, all Investigators have to 
inform their subjects and take care of appropriate follow-up and further treatment of the subjects. Ethics Committees and regulatory authorities will be informed about the reason and time of 
termination according to the applicable laws and regulations. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690739] return to the next scheduled visit to perform all required Early Termination (Early Discontinuation) visit activities and to collect and reconcile all study IMP.  If the subject does not return for the Early Termination (Early Discontinuation) visit, the site should fully document the reason for early termination. All data, including the date and primary reason for termination, must be recorded on the Early Termination (Early Discontinuation) case report form (CRF), and source document. 
Any subject who experiences an adverse event may be terminated from the study or from study 
treatment at any time at the discretion of the Investigator. In this case, the subject should be followed at the discretion of the Investigator until the resolution or stabilization of the AE. All applicable data should be recorded in the adverse events section of the case report form (CRF). If a subject terminates from the study early for multiple reasons that include adverse events, the Early Termination (Early Discontinuation) case report form should indicate that early 
termination was related to an adverse event.  
An exception to this requirement will be the occurrence of an adverse event that in the opi[INVESTIGATOR_531963] a prohibited medication, thereby [CONTACT_532007]. In such a case, the reason for discontinuation would be needed to take a prohibited medication, not the adverse event. 
The Investigator must inform the Medical Monitor and CRO as soon as possible of all subjects 
who are being considered for early termination due to adverse events. Additional reports must be provided when requested. The CRO will inform the Sponsor of this event.  
9 STUDY TREATMENT, DESCRIPTION AND ALLOCATION  
9.1 Investigational Medicinal Products (IMP) Description 
All study medications will be dispensed by [CONTACT_532008] a qualified Independent Dispenser 
designated by [CONTACT_079]. The Independent Dispenser will not be involved in performing any of the clinical assessments (IGA, lesion count, evaluation of signs and symptoms of local irritation, or evaluation of safety). 
The IMP will be dispensed only from the institution(s) approved by [CONTACT_154630]. 
The following treatments will be self-administered or administered by [CONTACT_31388]'s caregiver 
during this study. 
The IMP supplied in [ADDRESS_690740] of the following: 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690741]: TRIFAROTENE CREAM, 0.005% (Manufactured by 
[CONTACT_532009], Salt Lake City, UT for Teva Pharmaceuticals, Inc.) 
Reference 
Product: AKLIEF® (TRIFAROTENE 0.005% CREAM) 
(GALDERMA LABORATORIES, L.P., [LOCATION_003]) 
Placebo Control: Placebo (Vehicle) topi[INVESTIGATOR_68549] (Manufactured by [CONTACT_532010], Salt Lake City, UT for Teva Pharmaceuticals, Inc.) 
9.2 Storage and Handling Conditions  
x Store at 20 to 25 ÛC (68 to 77 ÛF) with excursions permitted to 15°to 30°C (59° to 86°F) 
in a secured, authorized access area at the investigative site. 
x Keep away from heat. 
x Keep out of reach of children. 
9.2.1 Packaging, Blinding and Labeling  
The IMP will be randomized, packaged and blinded by [CONTACT_532011] (Actavis 
Laboratories, Salt Lake City, UT). The labeling and packaging scheme will be outlined in a separate document by [CONTACT_1034]. The label content of IMP products will meet the requirements of ICH GCP guidelines, country specific guidelines and study protocol. 
The randomization will be pre-planned according to a computer-generated randomization 
schedule so that the test product, reference product and placebo are assigned in a 1:1:[ADDRESS_690742] will be packaged identically; an individual pump of study product (i.e., either Test, Reference or Placebo) will be packaged, as a “subject kit”. Each subject will be assigned to one kit.  
Using SyMetric System’s Interactive Web Response Technology system (i.e., IWRS), all 
subjects consented and screened into the study will be assigned a “Subject Number.” The Subject Number is the only subject identifier for subjects who are screened into the study (i.e., after being consented). The Subject Number is assigned, when a subject is screened into the study (i.e., after being consented). The study subject numbers will be assigned to study subjects sequentially in the order in which study subjects are enrolled into the study. The Subject Number will be an 8-digit number: comprised of a 2-digit Country number 3-digit Site number and 3-digit Sequence number.  
The system will also assign a study product kit number (based on the randomization schedule 
created by [CONTACT_117899]). The study product kit number is the identifying number listed on the study product dispensed to eligible (i.e., at each dispensing point in the study, at Visit 1, and 2 or 3 as required) subjects. The study product kit number is a 5-digit number. This will be the identifier used for randomized patients (i.e., randomization number). 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690743]'s eCRF. 
Each time a subject is dispensed study product (i.e., at Visit 1, and 2 or 3 as required, and when applicable unscheduled visit), the subject will receive a new study product kit number. The Subject Number and study product kit numbers will be recorded in the Subject Source and eCRF. Each subject will maintain the same subject number and treatment assignment throughout the study. 
A label will be attached to each of the pumps of study product.  The label will include at least the 
following information: Protocol number, subject number, study product kit number, space for subject’s initials, statement that the study product is for Investigational Use only, space for dispensing date and the Sponsor’s name. In addition, all subjects will be provided with written instructions on how to use the study product. . 
The study product will be blinded, packaged and delivered to the Investigative Site in bulk. The 
study medications will be shipped to the Investigator’s site from a centralized location.  
This is a double-blind clinical endpoint bioequivalence study. The IMP will be labeled and 
packaged such that neither the Subject nor any Investigator or study can identify the treatment. The Investigator, staff at the study site, study monitors, and data analysis/management personnel will be blinded to the treatment assigned to the subject. The study site will have at least one Independent Dispenser. The role of the unblinded Independent Dispenser will be to randomize, dispense and collect study medication to/from th e subjects, maintain dispensing records, and 
ensure the study medication logs are complete and accurate. The subject will be requested not to discuss the appearance of the study medication with the Investigator or study staff outside of the Independent Dispenser. Independent dispenser should not participate in any activities other than the activities defined in this section. 
The Principal Investigator [INVESTIGATOR_531964] a 
locked, secure location, with access limited to the Investigator and his/her designee(s). An accurate inventory of the study medication will be maintained in accordance with federal regulations. 
To ensure that information that could potentially bias handling of data is not disclosed, the 
packaging team will hold the randomization scheme until after database lock. At the end of the study, after all the clinical data has been entered and the study database has been locked, a copy of the randomization schedule will be sent to the statistician by [CONTACT_532012]. In addition, after the database has been locked, the packaging site will send each Investigative Site a sealed envelope containing the full study randomization scheme that should be retained with the study documents in the event of an FDA Inspection. 
9.2.[ADDRESS_690744]-party vendor of 
Catawba Research such that a non-study-assigned independent expert will allocate the subjects to one of the three treatment arms using a compu ter-generated automated process, i.e., Integrated 
Web Response System (IWRS). A copy of the randomization scheme (respective to that site) will be retained at the study site following the completion of the study and should be available to 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690745] will be assigned with a screening number, starting 
with three-digit site numbers followed by [CONTACT_14774]-digit number starting from 001 in chronological order of screening in each site (e.g., [ADDRESS_690746] who signed ICF and screened at site 01).  The sites will assign the subject the screening number and the number will be maintained outside SyMetric’s IWRS until a subject is randomized. 
9.[ADDRESS_690747] and the vehicle (placebo) control are assigned in a 1:1:[ADDRESS_690748] should wash their face with a non-medicated cleanser (provided by [CONTACT_1034]), and pat dry.

Skin should be allowed to dry for 20-[ADDRESS_690749] with the eyes, lips/mouth, angles/corners of the nose, open wounds and other mucous 
membranes should be avoided. Hands should be washed before and after applying the study medication. IMP should be applied in this manner daily for [ADDRESS_690750]’s diary. The 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690751] does not return the Diary, compliance cannot be determined. Subjects taking fewer than 75% or more than 125% of the required doses, or who miss the scheduled applications for more than 3 consecutive days will be considered non-compliant and will be excluded from PP population.
 
Compliance criteria are as outlined in the table below: 
For subjects who have completed the study:  
  Compliance Criteri
a 
Study 
Period Duration Scheduled 
Doses Not 
more than 125% (doses) Not 
less than 75% (doses) 
Randomized Treatment [ADDRESS_690752] Accountability  
It is the responsibility of the Principal Investigator [INVESTIGATOR_531965]. When a drug shipment is received at a study site, the Principal Investigator [INVESTIGATOR_287782]’s Designee (for the purposes of this study the Independent Dispenser) must inventory the drug and sign the receipt form provided with the shipment. The receipt form should be emailed as per instructions provided on the receipt.  A copy of the receipt should remain at the site. 
The Principal Investigator [INVESTIGATOR_531966] a locked, secure location, with access limited to the Investigator and his/her designee(s). The Investigator will not supply study test articles to any person not enrolled in this study, or to any physician or scientist except those named as sub-investigators. 
A Drug Accountability Log  will assist study site staff in maintaining inventory records of study 
drug and is necessary for monitoring. An accurate inventory of the IMP will be maintained by [CONTACT_531996], in accordance with federal regulations. Subject’s must return used, partially used or unused IMP to the Independent Dispenser, at the end of the study, (Visit 4) so that any remaining drug supplies can be accounted for and noted in the Drug Accountability Log.  
The certified copy of Drug Accountability Log must be provided to the study monitor at the 
conclusion of the study and the original should remain at the study site.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690753], other than the randomly selected for retention samples, will be returned to the Drug Labeling, Packaging and Shippi[INVESTIGATOR_117884] (Actavis Laboratories UT, Inc.)  or be destroyed at the site after study close-out following approval from the Sponsor, and final drug accountability is reconciled.   
9.[ADDRESS_690754] the sites participating in the study to meet the 
sample retention requirements of the US-FDA 21 CFR 320.38, 320.63, Guidance for Industry “Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c)” and the Guidance for Industry "Handling and Retention of BA and BE Testing Samples”. 
Samples of study drug will be randomly selected at the investigational site, in accordance with 
21 CFR 320.38, 320.63, Guidance for Industry “Compliance Policy for the Quantity of Bioavailability and Bioequivalence Samples Retained Under 21 CFR 320.38(c)” and the Guidance for Industry, “Handling and Retention of BA and BE Testing Samples”, regarding retention of study drug samples. and 21 CFR 320.36 for requirements for maintenance of records 
of bioequivalence testing. In addition, the Investigators should follow the procedures of 21 CFR 
58 and ICH E6, “Good Clinical Practice: Consolidated Guideline”, for retention of study records and data in order to conduct their studies in compliance with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP).  
Each reserve sample will be stored under conditions consistent with product labeling [Store at 
room temperature between 20°C - 25°C (68°F to 77°F)] and with access limited to authorized 
personnel. Each reserve sample will be retained for a period of at least [ADDRESS_690755] 9 
kits (ensuring [ADDRESS_690756], 3 are reference and 3 are placebo) from each shipment prior to dispensing to subjects and document on the Retention Sample Checklist. The selection process 
will ensure a sufficient amount of retention samples are retained as per Sponsor requirement. The number of subject kits kept for retention will be noted on the study product accountability form, as a retention sample, in addition to the retention sample log.
 The study site PI [INVESTIGATOR_531967], until shipment to a third-party repository.  
To ensure samples are not confused with investigational product for subject use and to ease the 
storage burden at a site, the randomly selected retention samples of investigational product will be transferred by [CONTACT_532013], an independent third-party storage facility for long term storage. To ensure compliance with product specific storage requirements, the original label should not be covered with a new shippi[INVESTIGATOR_7801]. If the retention samples are remaining at a site (eg. Belize sites ), the Standard Operating Procedure (SOPs) will 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690757] identified in the agency's request. The request has to be sent directly to an independent biorepository vendor by [CONTACT_532014]. The Sponsor (Teva Pharmaceuticals, Inc.) and CRO (Catawba Research) must be notified, and copi[INVESTIGATOR_287775]: 
 
Retention Samples 
Storage Facility   BioRepository Resources, LLC [ADDRESS_690758] New Providence, NJ [ZIP_CODE]  Glenn Bullett  President  Email: [EMAIL_10159]   Phone: ([PHONE_11007]  Fax: ([PHONE_11008]  Cell: ([PHONE_11013] Sponsor  
 Teva Pharmaceuticals, Inc,  [ADDRESS_690759], Bldg. A  Parsippany NJ [ZIP_CODE], [LOCATION_003]  Corrine Dias 
Associate Director, Global 
Gx. - Clinical Development 
& Operations  
Cell: [PHONE_11014] Email: [EMAIL_10161] Clinical Research 
Organization:   Catawba Research [ADDRESS_690760] Manager Office: Cell: [PHONE_11000]  Fax: ([PHONE_11015] Email: [EMAIL_10154]  
9.8 Return of Clinical Supplies  
Except for the retention samples, all used and unused pumps of IMP may be returned to the Drug 
Labeling, Packaging and Shippi[INVESTIGATOR_117884] (Actavis Laboratories UT, Inc.) for destruction or be destroyed at the site after study close-out following approval from the Sponsor, and final drug accountability is reconciled. 
It is important that retention samples and all used and unused pumps of IMP not be returned to 
CRO (Catawba Research) or the Sponsor (Teva) at the end of the study.  
9.[ADDRESS_690761] to use the non-medicated, non-comedogenic moisturizer; instructions for use will be provided.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 63 of 88 For the purpose of this study, the following items will be provided by [CONTACT_1034]: 
x Non-medicated cleanser  
x Sunscreen with SPF 15 or greater  
x Soft towels   
x Non-medicated moisturizing cream or lotion.   
10 STATISTICAL METHODS  
10.1 Scientific and Statistical Considerations of the Study Design 
The study was designed following FDA Draft Guidance on Trifarotene Recommended May 
[ZIP_CODE] and FDA Draft Guidance on Adapalene; Benzoyl peroxide Gel; topi[INVESTIGATOR_2855], Recommended 
Dec 2016; Revised Nov 2018, Nov [ZIP_CODE] and Guidance for Industry -Acne Vulgaris: 
Establishing Effectiveness of Drugs Intended for Treatment, May [ZIP_CODE]. 
 
10.1.1  Sample Size Rationale  
Sample size calculations are based on information from a Medical Review11 for developi[INVESTIGATOR_007] a 
bioequivalence study comparing Trifarotene cream 0.005% after 12 weeks of treatment.  It appears that an appropriate estimate for the percent reduction for inflammatory lesions for active treatments is 60% with that for vehicle treatment 12.3% lower, at 48.7% reduction.  For non-inflammatory lesions an appropriate estimate for percent reduction for active treatment is 53.5% with vehicle treatment at 39.6%.  The standard deviation for both inflammatory and non-inflammatory percent lesion reductions should be no more than 33% and 38% for active and vehicle treatments, respectively. 
The following assumptions were used in computer simulations to determine the sample size.  
Lesion 
Type Active  
% Reduction Active  
Std. Dev. (%) Vehicle  
% Reduction Vehicle  
Std. Dev. (%) 
Inflammator y 60.[ADDRESS_690762] equivalent efficacy and that 
approximately 82% of mITT subjects in a study will qualify for the PP population. 
Randomizing 765 subjects in the mITT (255:255:[ADDRESS_690763]:Reference:Placebo) and 627 in the PP 
(209:209:[ADDRESS_690764]:Reference:Placebo) should provide at least an 85% probability of showing that the 90% confidence intervals on the Test/Reference ratio of mean percent reduction from baseline, for both lesion types, are contained within the interval 0.800 to 1.250 in the PP 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690765] and Reference products are 
statistically superior (p<0.05) to the placebo in the mITT population. 
10.1.2  Unblinding Procedures  
This is a Randomized, Double-blind, Three-Arm, Placebo Controlled, Parallel design, multi-
centre study. Subjects will be randomly assigned in a 1:1:[ADDRESS_690766] and the vehicle (placebo) control. The randomization assignment will be generated using SAS
® by [CONTACT_55467] (SyMetric), not involved with the study. The 
treatment each subject will receive will not be disclosed to the Investigators, study center personnel, subject, sponsor, or CRO involved in the study conduct, monitoring, data review or analysis. 
SyMetric will hold the randomization code throughout the conduct of the study in order to 
minimize bias. If necessary, for the safety and proper treatment of the subjects, the Investigator can unblind the subject’s treatment assignment to conduct appropriate follow-up care. Whenever possible, the Sponsor or medical monitor will be notified before unblinding the study medication. The date and signature [CONTACT_532041]’s source documentation. 
The Investigator, staff at the study site, study monitors, and data analysis/management personnel 
will be blinded to the treatment assigned to the subject, with the exception of the Independent Dispenser. The study site will have at least one Independent Dispenser. The role of the unblinded Independent Dispenser will be to dispense and collect study medication to/from the subjects, maintain dispensing records, and ensure the study medication logs are complete and accurate. The subject will be requested not to discuss the appearance of the study medication with the Investigator or study staff outside of the Independent Dispenser. Independent dispenser should not participate in any activities other than the activities defined in this section.  
In case of an emergency, if the details of the study drug are required for management of an 
emergency as per the opi[INVESTIGATOR_118362], the Investigator can unblind the product that is received by [CONTACT_43966]. In case of non-emergency condition that requires study drug information for management of condition as per Investigator’s opi[INVESTIGATOR_1649], the Investigator should obtain Sponsor or medical monitor approval in writing prior to breaking of the blind. The unblinding can be performed through a computer-generated automated process, i.e., Interactive Web Response System (IWRS). It is recommended that all attempts should be made to maintain the study blind. However, in case that unblinding is performed, the reason for breaking the blind must be clearly documented in the source documentation and Case Report Form (CRF) and the subject must be discontinued from the study. 
The date on which the code was broken together with the identity of the person responsible must 
also be documented. 
The treatment assignments will remain bli nded until the final database is locked. 
 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 65 of 88 10.1.3  Significance Level  
All statistical tests will be two-sided at a significance level of Į = 0.05, unless otherwise 
indicated. No adjustment will be made for multiplicity. 
 
10.2 Datasets to be Analyzed  
Three analysis populations will be used in the analysis of the clinical data: 
a. The mITT and safety populations include all randomized subjects who use at least one 
dose of product (compliance review from Subject diary). 
b. The Per Protocol (PP) population includes all mITT Subjects who: 
1.  meet all inclusion/exclusion criteria,  
2. apply 75% to 125% of the scheduled applications of the assigned product, did not 
miss more than three consecutive scheduled applications,  
3. return for the 12-week evaluation within the visit window (± 4 days; i.e., study 
Day 80-88), 
4.  and have no protocol deviations that affect proper administration of the treatment 
or accurate evaluation of its effectiveness. 
Subjects who are discontinued early from the study due to lack of treatment effect (LOTE) after 
completing minimum four (4) weeks of treatment will be included in the PP population as treatment failures (i.e., non-responders) using the Last Observation Carried Forward (LOCF) approach. In addition, subjects whose condition or symptoms worsens and require alternate or supplemental or rescue therapy for the treatment of their condition during the treatment phase of the study should be discontinued, included in the mITT and PP population analysis using LOCF, and provided with effective treatment. The use of supplemental medicines and rescue medicine will be per standard of care (SOC) per medical judgement of the Investigator.  All supplemental and rescue medicines will include name, dose, frequency of administration, start and end dates, which is supplied to discontinued subjects for worsening of conditions.   
Subjects discontinued early for other reasons should be excluded from the PP population, but 
included in the mITT population, using the Last Observation Carried Forward (LOCF) approach.  
Lack of treatment effect (LOTE): After completion of at least [ADDRESS_690767] makes the decision to withdraw or discontinue from the study, then the reason for withdrawal/discontinuation will be  coded as “lack of treatment effect” (LOTE). 
The subject would be included in the PP population as a treatment failure using Last Observation Carried Forward (LOCF).  
 A shift table will be provided for any subject that has been discontinued with the reason of lack 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690768] to show changes from screening/baseline to time of discontinuation (last 
observation).  
10.[ADDRESS_690769]’s 
facial acne vulgaris using the Investigator’s Global Assessment (IGA) and the Lesion Counts. 
Local irritation/application site reactions such as erythema, dryness, burning/stinging, erosion, 
edema, pain and itching will be recorded at each  visit to allow a comparison between treatment 
groups. A detailed scale is presented. 
10.3.1  Demographics and Screening/Baseline/Randomization Characteristics   
Demographic and screening/baseline/randomization characteristics will be evaluated for 
comparability across treatment groups for the mITT, PP, and safety populations.  Continuous variables will be analyzed with an analysis of variance with factors of treatment and investigational site.  Categorical variables such as gender, ethnicity, and race will be analyzed with a Cochran-Mantel-Haenszel test, stratified by [CONTACT_76537].  
10.3.[ADDRESS_690770] 5% of the subjects in either treatment group will be evaluated using categorical methods. 
The concomitant medications used will be summarized by [CONTACT_1570]. Application site reactions such as erythema, dryness, burning/stinging, erosion, edema, pain and 
itching will be summarized for the safety population by [CONTACT_531991]. 
Safety analyses will be performed on the safety population. All safety data will be listed by 
[CONTACT_532015]. 
10.3.3  Efficacy Assessment  
[IP_ADDRESS]  Primary Endpoints  
The primary efficacy endpoints are the mean percent change from screening/baseline to week 12 
in the inflammatory (papules and pustules) and in the non-inflammatory (open and closed comedones) lesion counts.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 67 of 88 [IP_ADDRESS]  Test of Clinical Equivalence 
The evaluations of clinical equivalence will be performed for the PP population.  
For the primary efficacy assessment, the two-sided, 90% confidence interval on the 
test/reference ratio of the mean percent change from screening/baseline to week 12 in each lesion type will be calculated using Fieller’s method and the pooled variance estimate (MSE) obtained from a two-way Analysis of Variance (ANOVA) of the Test and Reference results. The statistical model for the ANOVA will contain terms for treatment and center. If the skewness of the residuals from the ANOVA is outside of -2 to 2, then a nonparametric approach will be used to obtain the confidence intervals. Bioequivalence will be established if the 90% confidence intervals for the ratio of test/reference means, for both inflammatory and non-inflammatory lesion counts, are contained within the interval [0.80, 1.25] using the per protocol (PP) population. 
[IP_ADDRESS]  Test of Superiority 
The evaluations of superiority will be performed using the mITT population.  
Superiority of the Test treatment versus the Vehicle and for the Reference treatment versus the 
Vehicle will be conducted separately. 
The test product and RLD will each be compared to that of the placebo group separately using 
ANOVA to evaluate if they are statistically superior at p<0.05 (two-sided test) to the placebo. Superiority will be established If the mean percen t change (reduction) from screening/baseline to 
week 12 for each active treatment, for both inflammatory and non-inflammatory lesion counts, is greater than, and statistically different fro m (p<0.05), that for the vehicle (placebo) Control.The 
statistical model for the ANOVA will contain terms for treatment and center. If the skewness of the residuals from the ANOVA is outside of -2 to 2, then a nonparametric approach will be used. 
[IP_ADDRESS]  Analysis of IGA scores 
Descriptive statistics using categorical methods to compare IGA Scores between each treatment 
group will be conducted and presented. No inferential analyses are planned. 
[IP_ADDRESS]  Analysis of Application Site Reactions 
Descriptive statistics using categorical methods to compare application site reactions between 
each treatment group will be conducted.  
 
10.4 Concomitant Medication 
The start and stop calendar date (e.g., dd/mmm/yyyy) and study day (e.g., Day X) of 
concomitant medication use should be provided in the data set in addition to the reason for the medication use. It should clearly be noted whether the medication was used prior to screening/baseline visit, during the study, or both. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690771]. A new condition or the worsening of a pre-existing condition will be considered an adverse event. Stable chronic conditions (such as arthritis) that are present before study entry and do not worsen during this study will not be considered adverse events. 
Accordingly, an adverse event can include any of the following: 
1. intercurrent illnesses 
2. physical injuries 
3. events possibly related to concomitant medication 
4. significant worsening (change in nature, severity, or frequency) of the disease under 
study or other preexisting conditions  
5. events occurring during diagnostic procedures or during any washout phase of this study 
6. laboratory or diagnostic test abnormalities that result in the withdrawal of the patient 
from the study, are associated with clinical signs and symptoms or a serious adverse event, or require medical treatment or further diagnostic work up, or are considered by [CONTACT_11150] (Note: Abnormal laboratory test results at the screening visit that preclude a patient from entering the study or receiving study treatment are not considered adverse events). 
7. side effects caused by [CONTACT_532016].  
 The potential adverse reactions of TRIFAROTENE CREAM, 0.005% (Teva Pharmaceuticals, 
Inc.) are anticipated to be similar to those observed with the use of AKLIEF® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., [LOCATION_003]). The skin of certain sensitive individuals may become excessively red, edematous, swollen, blistered or crusted, local erythema, peeling at the site of application. Temporary hyper- or hypopi[INVESTIGATOR_531968]. Trifarotene, like other retinoids, has been 
reported to cause severe irritation on eczematous skin and should be used with utmost 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 69 of 88 caution in patients with this condition. 
Worsening of the disease under study will be measured by [CONTACT_532017], and should be recorded as an adverse event only if the presentation and/or outcome is more severe than would normally be expected from the normal course of the disease in a particular subject.  
In this study, any adverse event occurring after the subject has signed the informed 
consent/assent form until the end of follow-up period should be recorded and reported as an adverse event. 
A treatment-emergent AE (TEAE) is any AE that occurs after initiation of study medication, or 
any event already present that worsens in either intensity or frequency following exposure to study medication.  
For adverse event recording, the study period is defined for each subject as that time period from 
signature [CONTACT_28513]/assent form through the end of the study (including the follow 
up period). All adverse events that occur during the defined study period must be recorded on the source documentation and CRF, regardless of the severity of the event or judged relationship to the study drug. For serious adverse events, the Serious Adverse Event Form must also be completed, and the serious adverse event must be reported immediately (see Section on Reporting below).  
At each contact [CONTACT_1155], the Investigator or designee must question the subject about 
adverse events by [CONTACT_23501]-ended question such as, “Have you had any unusual symptoms or medical problems since the last visit? If yes, please describe.” All reported or observed signs and symptoms will be recorded individually, except when considered manifestations of a medical condition or disease state. A precise diagnosis will be recorded whenever possible. When such a diagnosis is made, all related signs, symptoms, and any test findings may be recorded collectively as a single diagnosis on the CRF and, if it is a serious adverse event, also on the Serious Adverse Event Form. 
The onset and end dates and times, action taken regarding study drug, treatment administered, 
and outcome for each adverse event must be recorded on the source documentation. 
The relationship of each adverse event to study drug treatment, and the severity and seriousness 
of each adverse event, as judged by [CONTACT_737], must be recorded as described below. 
The clinical course of each adverse event will be monitored at suitable intervals until resolved or 
stabilized or returned to screening/baseline, until the subject is referred for continued care to a health care professional or until a determination of a cause unrelated to the study drug or study procedure
[1] is made. 
Adverse events will be coded according to MedDRA (Medical Dictionary for Regulatory 
Activities) and reported with respect to severity, duration, relationship to study medication(s), seriousness, outcome and action taken. 
 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690772] be recorded as 1 of the choices on the following scales: 
x Mild: No limitation of usual activities 
x Moderate: Some limitation of usual activities 
x Severe: Inability to carry out usual activities  
 
11.1.2 Relationship to Study Medication  
Adverse events will be assessed for the relationship to the study drug (causality) according to the 
following scale: 
 
TERM DEFINITION CLARIFICATION 
No 
Reasonable Possibility (not related) This category applies 
to 
those adverse events 
which, after careful consideration, are clearly due to extraneous causes (disease, environment, etc.) or to those adverse events, which after careful medical consideration at the time they are evaluated, are judged to be unrelated to the test drug. x An adverse experience may be 
considered 
x No Reasonable Possibility if it is 
clearly due to extraneous causes or when (must have two): 
x It does not follow a reasonable 
temporal sequence from the administration of the test drug. 
x It could readily have been produced 
by [CONTACT_423]’s clinical state, environmental or toxic factors, or other modes of therapy administered to the subject. 
x It does not follow a known pattern of 
response to the test drug. 
x It does not reappear or worsen when 
the dru
g is re-administered.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 71 of 88 Reasonable 
Possibility (related) This category applies 
to those adverse events for which, after careful medical consideration at the time they are evaluated, a connection with the test drug administration cannot be ruled out with certainty or felt with a high degree of certainty to be related to the test drug. x An adverse experience may be 
considered Reasonable Possibility related if or when (at least two of the following): 
x It follows a reasonable temporal 
sequence from administration of the 
drug. 
x It could not be reasonably explained 
by [CONTACT_20612]’s clinical state, environmental or toxic factors, or other modes of therapy administered to the subject. 
x It disappears or decreases on 
cessation or reduction in dose. There are important exceptions when an adverse event does not disappear upon discontinuation of the drug, yet drug relatedness clearly exists. 
x It follows a known pattern of 
response to the test dru
g. 
 
11.2 Serious Adverse Events  
An Adverse Event or Suspected Adverse Reaction  is considered ‘‘serious’’ if, in the view of 
either the investigator or sponsor, it results in any of the following outcomes: 
x Results in death  
x A life-threatening adverse event; (Note: the term “life-threatening” as used here refers 
to an event in which the Subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.)  
x Requires in-Subject hospi[INVESTIGATOR_1081]; This 
means that hospi[INVESTIGATOR_72444]/or prolongation of hospi[INVESTIGATOR_177564], or that they occurred as a consequence of the event. Hospi[INVESTIGATOR_177565], unless there was worsening of the pre-existing condition during the subject’s participation in this study.  
x Results in persistent or significant disabi lity/incapacity (substantial disruption of the 
ability to conduct normal life functions). 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 72 of 88 x Is a congenital anomaly/birth defect. 
x Any “other” important medical event.  
Important medical events that may not result in death, be life-threatening or require 
hospi[INVESTIGATOR_531969], based on appropriate medical judgment, they may jeopardize the Subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  
Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or the development of drug dependency or drug abuse. Note: Any suspected transmission of an infectious agent via a medicinal product is considered an important medical event. 
An adverse event that does not meet any of the criteria for seriousness listed above will be 
regarded as a non-serious adverse event. 
Regardless of the above, any additional adverse events, which the Principal Investigator 
[INVESTIGATOR_531970], should be immediately reported to the CRO (Catawba Research). 
11.2.1 Expectedness 
The sponsor’s Pharmacovigilance Department will determine the expectedness for all serious 
adverse events. CRO and Investigators will not determine the expectedness. 
An AE which is not included in the adverse ev ents section of the relevant Safety Information 
Reference by [CONTACT_16972], severity, outcome or frequency is considered an unexpected adverse event. 
The reference safety information for this study is AKLIEF® (TRIFAROTENE 0.005% 
CREAM) (GALDERMA LABORATORIES, L.P., US A, Prescribing Information to use as 
reference for safety information is to be found in Appendix II. 
 
11.3 Reporting of Serious Adverse Events (SAEs) 
To satisfy regulatory requirements, all serious adverse events (as described in Section 11.3) that 
occur during the study period (including the protocol defined follow up period) regardless of judged relationship to treatment with the study drug, must be reported to Teva’s Lead Safety Officer (LSO) on their PV team and CRO in parallel, by [CONTACT_737]. The event must be reported within 24 hours of when the Investigator learns about it. Completing the serious adverse event form (preferably in English) and reporting the event must not be delayed, even if not all the information is available. Subsequently, the CRO will communicate this information with the Teva Clinical Manager (Sponsor) and Medical Monitor (MM) in parallel (and any other contacts identified in the Safety and Medical Monitoring Plan (SMMP)) within 1 business day (in some studies an SAE email distribution list may be used). If there is no LSO, then according to the SMMP. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690773] be reported in parallel to the following persons: 
1. Appropriate Pharmacovigilance (PhV) unit: 
Email:  [EMAIL_2368]  
2. Catawba Research Safety Group: 
Email: [EMAIL_10162]  
Catawba Research will communicate the details of the SAE with the Sponsor: Sponsor’s Contact [CONTACT_532018] (copy of the SAE details for information purposes only) Name: [CONTACT_532042]: [PHONE_11014] E-mail: [EMAIL_10163]  
  
Name: [CONTACT_532043]: ([PHONE_11016] Email: [EMAIL_10164]  
 
The SAE form should be completed, preferably in English. The SAE form completion and 
reporting must not be delayed even if all of the information is not available at the time of the initial contact. Additional information (follow-up) about any SAE unavailable at the initial reporting should be forwarded within 24 hours of the information becoming available to the same address as the initial report.  
It should be considered that Day 0 is the day a Teva employee, or an employee of a company 
which Teva has a contractual arrangement with, becomes aware of a case which fulfils the minimum criteria for reporting. Note: If the investigator calls a Teva representative or CRO representative, this will count as Day [ADDRESS_690774] informed the Director of Health Services of the Ministry of Health Belize, then they will follow the same procedures as the US sites. 
The reporting timelines for reporting of SAE’s by [CONTACT_532019] (if 
applicable) (depending on the type of study) is within 24 hours. If the Investigator exceeds 24 hours to report the SAE, this should be identified as a protocol deviation and documented accordingly. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 74 of 88 In case, the Investigator fails to report any serious adverse event within the stipulated period, 
he/she shall have to furnish the reason for the delay to the satisfaction of the IRB along with the report of the serious adverse event. The report of the serious adverse event, after due analysis, shall be forwarded by [CONTACT_532020], Sponsor (Teva) and CRO (Catawba Research) within fourteen days of the occurrence of the serious adverse event as referred in clause (ix)-section 35 of Part-B of Chapter-V of New Drugs & Clinical Trial Rules; 2019. The study site must transmit the SAE form through an email to [EMAIL_10162] , and Teva 
contacts listed above.   
 These SAE reports must contain the following information, preferably using the template 
provided by [CONTACT_1034]: 
A. Study name/number B. Study Drug C. Investigator details (name, phone, fax, e-mail) D. Subject Number E. Subject Initials when appropriate F. Subject Demographics G. Clinical Event 
1) Description 2) Date of onset 3) Treatment (drug, dose, dosage form) 4) AE Relationship to study drug 5) Action taken regarding study drug in direct relationship to the AE 
H. If the AE was Fatal: 
1) Cause of death (whether or not the death was related to study drug) 2) Autopsy findings (if available) 
Each report of a serious adverse event will be reviewed and evaluated by [CONTACT_532021], study procedures, and to underlying disease. 
 For studies conducted in [LOCATION_003]:  It is the responsibility of the CRO to report a Serious Adverse 
Event (SAE) to the FDA within proper time constraints as per the Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies – please refer to the most current version. Confirmation of submission of this report must then be provided to Teva’s study representative as well as their Pharmacovigilance department (contact [CONTACT_117908]). 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 75 of 88 The timeliness for submission of expedite reports should be 15 days or 7 days (death cases) or as 
otherwise specified in local regulations. 
The CRO will take on the responsibility of reporting SAEs to the Investigators and/or to the 
Ethic Committee. 
Any serious adverse event will be reported to competent authority and ethics committee 
according to the country specific requirements and the responsibilities defined above. All AEs will be reported in the Clinical Study Report with the complete information named above according to the requirements of the Note for Guidance on Structure and Content of Clinical Study Reports (CPMP/ICH/137/95). 
 Subjects who have had an SAE during the study must be followed clinically until all parameters 
(including laboratory) have either returned to normal or have stabilized or are otherwise explained. The Investigator does not need to actively monitor subjects for new serious adverse events once the study has ended. However, serious adverse events occurring after a subject ended the study should be reported to the Sponsor if the Investigator becomes aware of them. 
   
11.[ADDRESS_690775] been surgically sterilized (by *hysterectomy or bilateral oophorectomy) or have been postmenopausal for at least [ADDRESS_690776].  
Alternatively, any of the following methods of birth control are acceptable: oral or injectable 
contraceptives, contraceptive patches, medroxyprogesterone acetate (ex. Depo-Provera
®) with 
stabilized use for at least 3 months), vaginal contraceptive (etonogestrel/ethinyl estradiol vaginal ring (ex. NuvaRing
®)) contraceptive implant with etonogestrel or equivalent, double barrier 
methods (e.g., condom and spermicide), IUD, abstinence.  
If a subject who was abstinent becomes sexually active during the study, a 2nd acceptable method 
of birth control should be used and documented. Prior to study enrollment women of childbearing potential must be advised of the importance of avoiding pregnancy during study participation.  
*Full hysterectomy or bilateral oophor ectomy considered surgically sterile. Tubal ligation is not considered 
equivalent to female sterilization. 
A negative result of a pregnancy test having a minimum sensitivity of at least 25 mIU/ml for 
hCG should be obtained, prior to study procedures, at Visit 1.  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 76 of 88 Pregnancy testing will also be performed at every study visit and the results of all pregnancy 
tests (positive or negative) will be documented. Subjects must have a negative urine pregnancy to continue in the study. 
  All pregnancies of women participating in the study that occur during the study, or within at least 
[ADDRESS_690777]/patient becoming pregnant during the screening period (i.e., before study 
drug administration) will be considered a screen failure and will not be allowed to rescreen. The Investigator is not required to report such pregnancies, provided no protocol-related procedures with known risk on pregnancy were applied. 
Any female subject becoming pregnant during the study will discontinue treatment.  All subjects 
who become pregnant will be monitored for the outcome of the pregnancy (including 
spontaneous or voluntary termination). If the pregnancy continues to term, the outcome (health of the infant up to 8 weeks of age), including details of birth and presence or absence of any birth defect, congenital abnormalities, or maternal and newborn complications, will be reported to the Sponsor. Any complication of pregnancy during the study and any complication of pregnancy that the Investigator becomes aware of after termination from the study will be reported as an adverse event or serious adverse event, as appropriate. 
11.5 Follow Up of Subjects 
The staff of the clinical facility/site has to monito r the clinical trial subject's safety from the 
occurrence of an AE until satisfactory recovery. 
The clinical course of each adverse event will be monitored at suitable intervals until resolved or 
stabilized or returned to screening/baseline, until the subject is referred for continued care to a health care professional or until a determination of a cause unrelated to the study drug or study procedure is made. 
Any AE which remains unresolved at the time point of subject’s last visit requires detailed 
evaluation and follow-up until the AE has been resolved or a reasonable explanation for its persistence is found; in case of AEs related to the IMPs every effort has to be made to follow-up clinical trial subjects to determine the final outcome. If follow-up cannot be completed until release of CRF by [CONTACT_532022]. In this case, follow-up information will be documented separately in the subjects’ record and outcome including a short description on follow-up procedures performed must be sent to the sponsor. 
It is the Investigator’s responsibility to assure that subjects experiencing adverse reactions will 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 77 of 88 receive definitive treatment for any adverse reaction, if required. Details of follow-up care are to 
be provided (i.e., if treatment or hospi[INVESTIGATOR_59029]). The responsibility to provide adequate follow-up for AEs includes periodically repeating laboratory tests yielding clinically abnormal results at the end of study evaluation. 
11.[ADDRESS_690778]'s source documents (and in the eCRF), regardless of whether or not an adverse event occurs as a result.  
The following are types of medication errors and special situations:  
1. Medication error: Any unintentional error in the prescribing, dispensing, or 
administration of a medicinal product while in the control of the healthcare professional, patient, or consumer. 
2. Overdose: Administration of a quantity of a medicinal product given per administration 
or cumulatively which is above the maximum recommended dose according to the authorized product information. Clinical judgment should always be applied. 
3. Misuse: Situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the authorized product information or the study protocol. 
4. Abuse: Persistent or sporadic, intentional excessive use of medicinal products which is 
accompanied by [CONTACT_3584]. 
5. Occupational exposure: Exposure to a medicinal product, as a result of one’s professional 
or non-professional occupation. 
6. Lack of efficacy. 
11.7 Reconciliation of SAEs & Pregnancy 
It is the CRO responsibility throughout the course of the study, to maintain a listing of all SAEs 
and pregnancy reports. At the conclusion of the study, in the case that NO SAE/pregnancy occurred, the CRO should send an email to Teva Global PV to indicate that no SAE/pregnancy occurred during the study. In the case that a SAE/pregnancy did occur, the CRO should send an email to PV requesting the reconciliation line listing. The CRO should perform a reconciliation of the SAEs in the study with those in the Teva Global PV database. 
All communication regarding Safety Data Reconciliation should be directed to the Teva Global 
PV email address:  [EMAIL_10165] 
 
11.[ADDRESS_690779] possible transmission of 
COVID-19. All sites should develop a detailed plan or SOP on how to mitigate risks of exposure 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690780] participants and study staff while maintaining study integrity. 
SOPs/site specific plan should include methods to reduce the amount of time spent by [CONTACT_532023]. 
At each visit, temperature check and COVID-19 symptom (such as tuffy or runny nose, sore 
throat, shortness of breath (difficulty breathing), cough, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, vomiting, diarrhea, loss of sense of taste and smell) screening for study subjects and site staff will be performed. At each visit, site should also ensure, subject exposure to others with suspected or confirmed SARS-CoV-2 infection.  
Study subjects and site staff should wear appropriate personal protective equipment/masks and 
practice hand sanitization methods. Site should ensure physical distancing (maintaining at least 6 feet between people) and take appropriate action to prevent possible infection from the COVID viruses as an important strategy where possible. Sites should assign only one participant per room, while performing any general safety evaluations or assessments and should disinfect the room once the participant leaves. 
Care should be taken to ensure study integrity and scientific validity of the data generated due to 
modifications to study conduct or design. Subject that has tested positive for COVID-19 during the trial may be discontinued from the study as per investigator’s discretion.  
12 ETHICS  
12.1 IRB/Ethics Committee 
IRB/Ethic committee (IRB/EC) approval will be obtained from an EC registered with FDA. PI 
[INVESTIGATOR_531971]/EC approval of the protocol, ICF, advertising material and all documents required as per applicable regulations before the study may begin at the study sites. Site shall maintain all the study records for no less than 5 years from the date of study completion or termination of the trial. PI [INVESTIGATOR_531972]/EC’s annual renewal to the Sponsor or Catawba Research and provide any IRB/EC approvals of revisions to the informed consent or protocol amendments.  
The PI [INVESTIGATOR_531973]/EC, any new information that may adversely affect the 
safety of subjects or the conduct of the study. Similarly, the PI [INVESTIGATOR_531974]/EC annually, or more frequently if requested by [CONTACT_1201]/EC. Upon completion of the study, the PI [INVESTIGATOR_298293]/EC with a brief report of the outcome of the study, if required.   
12.[ADDRESS_690781] of the Study 
This study will be conducted, and the informed consent will be obtained according to the ethical 
principles stated in the Declaration of Helsinki (2013), FDA regulations, the applicable guidelines for GCP and/ or the applicable local drug and data protection laws and regulations. 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690782] important considerations and 
should prevail over interests of society and science.  
12.3 Informed Consent/Assent 
The Principal Investigator [INVESTIGATOR_531975]/or their legally acceptable representative 
(i.e., parent or guardian) are clearly and fully informed about the purpose, potential risks and other critical issues regarding clinical studies in which they volunteer to participate. The principles of Informed Consent/Assent, according to FDA Regulations and ICH GCP will be followed. A copy of the proposed consent/assent form must be submitted to the IRB/IEC, together with the protocol, for approval. Prior to beginning of the study, the Principal Investigator [INVESTIGATOR_314351]/IEC’s written approval of the written informed consent/assent form and any other information to be provided to Subjects. 
• The Investigator or the Investigator’s representative will explain the nature of the study, 
including the risks and benefits, to the potential participant [or their legally authorized representative and answer all questions regarding the study. 
• Potential participants must be informed that their participation is voluntary. They [or their 
legally authorized representatives] will be required to sign a statement of informed consent 
that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, privacy and data protection requirements, where applicable, and the IRB/IEC or study center. 
• The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF. 
• Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study. 
• A copy of the ICF(s) must be provided to the participant [or their legally authorized 
representative]. 
Informed consent/assent will be obtained from all subjects using the following procedure: 
Subjects who are 18 years of age or older (up to the age of 40) must have provided IRB/IEC approved written informed consent. Subjects [ADDRESS_690783] provided IRB/IEC approved written assent. Written assent must be accompanied by [CONTACT_2717]/IEC approved written informed consent from the Subject’s legally acceptable representative (i.e., parent or guardian). Prior to initiating screening for the study, Subjects will be given the approved ICF/assent describing the study and any risks associated with participation. The Subject will be allowed as much time as needed to read and understand the information presented in the consent/assent form. Appropriate study personnel will be available to answer any questions the Subject might have regarding the study or study-related procedures. If the Subject chooses to participate in the study, he or she will be asked to sign and date the consent/assent form and will be provided with a copy for his or her records. Both the ICF and 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 80 of 88 assent (if applicable) must be signed by [CONTACT_532002]’s legally acceptable 
representative (i.e., parent or guardian) before any protocol assessments can be undertaken. 
 
12.[ADDRESS_690784] Confidentiality  
The monitor(s), the auditor(s), IRB/IEC, and the regulatory authority(ies), will be granted direct 
access to the Subject’s original medical records for verification of the clinical trial procedures and/or data, without violating the confidentiality, to the extent permitted by [CONTACT_280749] a written informed consent form, the Subject or the Subject’s legally acceptable representative is authorizing such access. 
The identity of the Subject will not be made publicly available and will be kept confidential and, 
to the extent permitted by [CONTACT_532024] [ADDRESS_690785]’s identity will remain confidential. 
13 DOCUMENTATION  
13.1 Site Regulatory Documents Required for Initiation  
At a minimum, the following documents will be received by [CONTACT_532025]:  
1. Completed and signed FDA Form 1572 
2. Current curricula vitae, signed and dated for the Principal Investigator [INVESTIGATOR_94582]-
Investigators named in the FDA form 1572 (current within 2 years) 
3. Current medical licenses of the Principal Investigator [INVESTIGATOR_94582]-Investigator named in 
FDA form 1572 
4. Documentation of IRB/IEC approval of this study protocol, Principal Investigator [INVESTIGATOR_531976]/assent forms  
5. Current IRB/IEC membership list or roster  
6. Fully executed protocol, and a copy of the protocol agreement page and any applicable 
amendments signed by [CONTACT_079]  
7. Documentation of “No Objection” to proceed from the local regulatory agency, wherever 
applicable. 
8. Non-disclosure Agreements for the investigator site named in FDA form 1572 
9. Financial Disclosure Statement for the Principal Investigator [INVESTIGATOR_94582]-Investigator 
named in FDA form 1572. 
10. Statement of Non-Debarment 
 
13.2 Maintenance and Retention of Records  
It is the responsibility of the Principal Investigato r to maintain a comprehensive and centralized 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690786] two years 
following final approval of the drug and/or notification from the Sponsor. These regulatory documents should be retained for a longer period if required by [CONTACT_31665]. These records include documents pertaining to the receipt and return of drug supplies, IRB/IEC, informed consent, source documents. No documen ts shall be transferred from the site or 
destroyed without first notifying the Sponsor. If the Principal Investigator [INVESTIGATOR_87674], the records shall be transferred to a mutually agreed upon designee in agreement with Catawba Research and Sponsor. Notice of such transfer will be given in writing to the Sponsor. 
The Principal Investigator [INVESTIGATOR_531977] a control in the investigation. Data reported on the CRF, which are derived from source documents, must be consistent with the source documents.  
   
13.3 Data Collection and Reporting  
Data for individual subjects will be collected on eCRF. The data management system will be 
Electronic Data Capture (EDC). The Investigator and his/her study site personnel will be 
responsible for completing the eCRFs. The Investigator is required to verify that all of the requested information is accurately recorded in the eCRFs. All information requested in the eCRFs needs to be supplied, including subject identification, date(s), assessment values, etc., and any omission or discrepancy will require explanation. All information on eCRFs must be traceable to source documents.  
Source documents such as the clinic chart (medical records specifically collected for the study 
information) are to be maintained separately from the eCRF in order to allow data verification. Because of the potential for errors, inaccuracies and illegibility in transcribing data into eCRFs, originals of laboratory and other test results must be kept on file. Source documents and copi[INVESTIGATOR_531978]. The following should also be available for review:   
1. Subject Screening Log  – documenting all subjects screened for participation in the study 
and reflecting their eligibility status. If ine ligible, the reason the subject was ineligible 
should be documented 
2. Delegation of Authority / Study Personnel Signature [CONTACT_94618]  – all site personnel will be 
listed along with their responsibilities and signatures; to be maintained at the site 
throughout the study 
3. Monitoring Log  – the date and purpose of all monitoring visits by [CONTACT_532026]/Sponsor/Designee will be documented 
4. Enrollment Log  – documenting Subject initials and start and end dates for all subjects 
enrolled 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 82 of 88 5. Drug Inventory/Packing Slip  – reflecting the total amount of drug shipped to the site 
and received and signed by [CONTACT_079] 
6. Drug Accountability Log  – reflecting the total amount of IMP dispensed to and returned 
by [CONTACT_94612] 
7. Informed Consent Form and Assent Form  – which must be available for each Subject 
and be verified for proper documentation 
The study monitor will be responsible for reviewing and verifying the data recorded in the 
eCRFs, utilizing the original source documentation and will query discrepant findings. The Investigator and study site personnel will be responsible for answering all queries. All queries issued by [CONTACT_532027]. 
 
13.[ADDRESS_690787]’s medical notes. These documents, which are considered “source data”, should include documentation of:  
1. Demographic information  
2. Evidence supporting the diagnosis/condition for which the Subject is being studied  
3. General information supporting the Subject’s participation in the study  
4. General history and physical findings  
5. Hospi[INVESTIGATOR_94585] (if applicable)  
6. Each study visits by [CONTACT_568], including any evaluations, relevant findings/notes by [CONTACT_1268](s), occurrence (or lack) of adverse events and changes in medication usage, including the date the study drug commenced and completed.  
7. Any additional visits during the study  
8. Any relevant telephone conversations with the Subject regarding the study or possible 
adverse events  
9. An original, signed informed consent form/assent form (as applicable) for study 
participation  
10. Subject Diary 
The Principal Investigator [INVESTIGATOR_94586]/reports of 
tests/procedures performed as a requirement of the study. During monitoring visits, the monitor will need to validate data in the eCRFs against these sources of data.  
 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 83 of 88 13.5 Study Monitoring  
The study will be monitored by a representative of the CRO/sponsor (as applicable) to assess 
compliance with the protocol, ICH-GCP and applicable regulations. The Principal Investigator [INVESTIGATOR_94587] a monitor prior to the study and at regular intervals during the course of the study. These visits are for the purposes of verifying adherence to the protocol. 
The study monitor will review the Informed Consent/Assent Forms and verify eCRF entries by 
[CONTACT_94614] (hos pi[INVESTIGATOR_307]/clinic/office records) that will be made 
available for this purpose. The monitor will revi ew the maintenance of regulatory documentation 
and drug accountability. The monitor will review on a regular basis the progress of the study with the Principal Investigator [INVESTIGATOR_94588].  
eCRF sections may be monitored during these visits. At the end of the study, a closeout 
monitoring visit will be performed. Monitoring visits will be arranged in advance at a mutually acceptable time with site personnel. Sufficient time must be allowed by [CONTACT_532028]. The Study Coordinator and/or Principal Investigator [INVESTIGATOR_531979]. Adequate time and space for these visits should be made available by [CONTACT_079]. 
13.6 Audits and Inspections  
During the study and/or after it has been completed, one or more site visits may be undertaken 
by [CONTACT_94616]. The purpose of the audit is to determine whether or not the study is being conducted and monitored in compliance with the protocol, recognized GCP guidelines and all applicable regulations. 
Additionally, the study may be inspected by [CONTACT_17513]. These inspections may take 
place at any time during the study and/or after it has been completed.  
THE INVESTIGATOR MUST NOTIFY THE CLINICAL RESEARCH ORGANIZATION 
AND/OR SPONSOR PROMPTLY OF ANY INSPECTIONS SCHEDULED BY [CONTACT_94617], AND PROMPTLY FORWARD COPI[INVESTIGATOR_94590]. 
 
13.[ADDRESS_690788] documented approval from the Sponsor and the IRB/IEC prior to implementation.  
The only circumstance in which an amendment may be initiated without prior IRB/IEC approval 
is to eliminate apparent immediate hazards to a Subject or Subjects. However, the Principal 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-[ADDRESS_690789] notify the Sponsor immediately and the IRB/IEC within [ADDRESS_690790] that is NOT approved by [CONTACT_1201]/IEC prior to its initiation or implementation, OR deviation from standard operating procedures, Good Clinical Practices (GCPs), federal, state or local regulations. 
[ADDRESS_690791] all other relevant data and 
records to the CRO.  
The Principal Investigator [INVESTIGATOR_94591] a final report to the IRB/IEC and the Sponsor 
within one (1) month of study completion or discontinuation.  CRO must submit a final report as agreed in the Study Agreement for this study between Sponsor and CRO. 
15 REFERENCES  
1. Kurokawa I, Layton AM, Ogawa R. Updated Treatment for Acne: Targeted Therapy Based 
on Pathogenesis. Dermatol Ther (Heidelb). 2021 Aug;11(4):1129-1139 
2. Baldwin H, Webster G, Stein Gold L, Callender V, Cook-Bolden FE, Guenin E. 50 Years 
of Topi[INVESTIGATOR_531980]: Evolution of Treatment. Am J Clin Dermatol. 2021 May;22(3):315-327. 
3. Bell KA, Brumfiel CM, Haidari W, Boger L. Trifarotene for the Treatment of Facial and 
Truncal Acne. Ann Pharmacother. 2021 Jan;55(1):111-116 
4. FDA Guidance for Industry. Acne Vulgaris: Establishing Effectiveness of Drugs Intended 
for Treatment. Food and Drug Administration. May 2018. 
5. FDA Label (DailyMed) for Trifarotene Revised: Oct 2019 
6. FDA’s Draft Guidance on Trifarotene (May 2021) 
7. FDA’s Draft Guidance on Adapalene; Benzoyl peroxide (gel, 0.3%; 2.5%), 
Recommended Dec 2016; Revised Nov 2018, Nov 2019. 
8. Guidance for Industry. Handling and Retention of BA and BE Testing Samples. Office of 
Generic Drugs. FDA. May 2004. 
9.  Guidance for Industry “Compliance Policy for the Quantity of Bioavailability and 
Bioequivalence Samples Retained Under 21 CFR 320.38(c) 
10. FDA Guidance for Industry. Protecting Participants in Bioequivalence Studies for 
Abbreviated New Drug Applications During the COVID-19 Public Health Emergency. January 2021.   
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 85 of 88 11. FDA Summary Basis of Approval. Alkief # 211527 October 2019   
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 86 of 88 15.1 APPENDIX I: Revision History 
Version #  Affected Sections 
Final 1.0 
(13Ma y2022) N/A (new) 
Final 2.0 1.  Section 9.2.1 Packaging, Blinding and Labeling: 
Revisions made to account for change in IMP pump label to not use 2-part scratch off label 
2. Study Population - Inclusion Criteria #3 (Page 14): 
Removed the word “treatment” 
3. Section 5.1.1 – Inclusion Criteria #3 (Page 29): 
Removed the word “treatment” 
4. Section 9.2.3 – Subject Screening Number (Page 59) 
Revised Screening Number to include a three-digit Site Number, instead of a two-digit Site Number 
5. Section 10.1.2 - Unblinding Procedures (Page 64): 
Removed scratching off the tear off blinding label on IMP as a way to perform unblinding 
In addition, administrative and editorial changes have been 
made throughout the version 2 protocol to improve readabilit
y and s yntax 
 
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 87 of 88 15.2 APPENDIX II: AKLIEF-trifarotene cream package insert 
  
  
  
 
 
 
Final Version 2.0       Confidential  Protocol: TRIF-2101   Page 88 of 88  
Certificate Of Completion
Envelope Id: 0D9D795CDE6B46F79AE5D83DDB6190BA Status: Completed
Subject: Please DocuSign: TRIF-2101_Protocol_Version 2.0_30Jun2022_FINAL_Med Monitor Signed_AS_Stats Sig...Source Envelope: Document Pages: 88 Signatures: 2 Envelope Originator: Certificate Pages: 5 Initials: 0 Rhiannon TwentymanAutoNav: EnabledEnvelopeId Stampi[INVESTIGATOR_007]: DisabledTime Zone: (UTC) Dublin, Edinburgh, Lisbon, LondonTeva Pharmaceutical Industries Ltd
124 Dvora HaNevia' StreetTel Aviv, Tel Aviv  [EMAIL_10166]
IP Address: [IP_ADDRESS] 
Record Tracking
Status: Original
             21-Jul-2022 | 12:29Holder: Rhiannon Twentyman
             [EMAIL_10167]: DocuSign
Signer Events Signature [CONTACT_532044]
[EMAIL_10168] Level: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Pre-selected Style
Signature [CONTACT_5883]: 7B968E12-BC8C-4A71-90F4-4D6216D94A4AUsing IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab):    I approve this documentSent: 21-Jul-2022 | 12:31
Resent: 21-Jul-2022 | 17:25Viewed: 21-Jul-2022 | 17:27 Signed: 21-Jul-2022 | 17:[ADDRESS_690792] and Signature [CONTACT_59773]: 
      Accepted: 21-Jul-2022 | 17:27
      ID: 9a98deda-ac2a-4909-9f6a-80152e4cf01a
Nageshwar Thudi
[EMAIL_10169]-Global GX PD/CE and BioSSecurity Level: Email, Account Authentication 
(Required)
Signature [CONTACT_59772]: Pre-selected Style
Signature [CONTACT_5883]: D62E5615-92CE-4625-816A-800F64AB3ABE
Using IP Address: [IP_ADDRESS]
With Signing Authentication via DocuSign password
With Signing Reasons (on each tab): 
   I approve this documentSent: 21-Jul-2022 | 12:31
Viewed: 21-Jul-2022 | 12:51 Signed: 21-Jul-2022 | 12:[ADDRESS_690793] and Signature [CONTACT_59773]: 
      Accepted: 18-Aug-2021 | 19:53
      ID: a378347d-e595-4878-845c-3faaaf439fa2
In Person Signer Events Signature [CONTACT_59774]/Encrypted 21-Jul-2022 | 12:31
Certified Delivered Security Checked 21-Jul-2022 | 12:51Signing Complete Security Checked 21-Jul-2022 | 12:55Completed Security Checked 21-Jul-2022 | 17:[ADDRESS_690794] and Signature [CONTACT_532045] (“ Notice ”) is provided by [CONTACT_532029]. and the Teva entity with which 
you communicate in relation to signed documents (" Teva ”).You can view a list of all the Teva affiliates at 
the following website:  http://www.tevapharm.com . Teva is referred to in this Notice as “ we”, “us” and 
“our.” 
1. Scope of this Notice  
This Notice describes how we use your personal da ta when we ask you to sign a certain document 
electronically in the system of our service provider , DocuSign, and when we deliver signed documents to 
you. In this way, we can exchange communication el ectronically, which is faster than exchanging paper 
documents.  
You may also decide to register in the DocuSign system, which is a separate service provided by 
[CONTACT_532030] a separate controller and is governed by  [CONTACT_532031]. Teva is not responsible for the 
privacy policies or practices of DocuSign related to such registration.  
The Notice applies to our staff (including employees and external consultants), to our vendors/partners 
and their staff, and to healthcare professionals to  whom we may deliver documents via DocuSign with a 
request for them to sign the documents electronically.  
2. Scope of data we process  
In order to use DocuSign, and in part icular, in order to invite you to sign documents, guarantee security 
and accountability, and manage documents after they  have been signed, we may need to use some of 
your personal data, e.g. name, surname, email address and phone number, or a token and details 
regarding the document signed and when it is signed.   
If we do not have all the information necessary in or der to use DocuSign (e.g. your email), we will ask you 
to share such information with us. If you decline, docu ments will be signed and circulated traditionally in 
paper form (which may take longer).  
3. How We Use Your Information  
We generally process your data for the purpos es described in our general website privacy 
policy https://www.tevapharm.com/our-company/corporate-governance/data-privacy/  or in other polices 
you may have received from us (e.g. employee privacy policy).  
We may want or need to communicate with you for a number of legitimate purposes described in such 
privacy policies (e.g. to respond to your queries or  other correspondence, to meet legal, regulatory, 
pharmacovigilance and compliance requirements, or to perform our contract with you or your employer).  
Instead of doing so in traditional paper form, we offe r a tool that allows us and you to communicate and 
sign documents safely via electronic means and to gu arantee accountability (the availability of signed 
documents).  You may print out a document signed  and delivered via DocuSign for a limited period 
(usually 30 days) after such documents are first sent  to you. Afterwards, you may ask us to send you 
paper copi[INVESTIGATOR_531981].  
We process such data for our legitimate  business purposes  to assure safe and accountable electronic 
communication and electronic signing and delivering of documents.  
Legitimate Interests    	
" #	
	
! 
You can find more information regarding Teva&apos;s legitimate interest balancing test by [CONTACT_532032] "Your Rights" section below.  
Sharing Your Personal Data  
Teva discloses your personal data to th e following categories of recipi[INVESTIGATOR_840]:  
x our staff (including employees and external co nsultants), professional advisors and agents.  
x DocuSign, the provider of the electronic signat ure system, which acts as a third-party service 
provider that processes your personal data on behalf of Teva and which is bound by [CONTACT_532033], but which also acts 
as a separate and independent controller (if you us e their other services, e.g. if you register with 
them);  
x other functions and companies in the Teva group of companies worldwide.  
x other third-party service providers that process yo ur personal data on behalf of Teva and which 
are bound by [CONTACT_532034], such as IT support.  
Cookies and Related Tracking Technologies  
For information on cookies and related tracking technologies, please visit the cookie notice of DocuSign 
at https://www.docusign.com/company/cookie-policy . 
How We Store Your Information  
Confidentiality and Security of your personal data  
Teva maintains data integrity by [CONTACT_532035]/or against 
accidental loss, disclosure, access or accidental or  unlawful destruction or misuse of personal data.  
Teva’s employees and data processors who act on behalf and under the instructions of Teva are 
contractually bound to use these data only for purposes regarding the performance of their contractual 
obligations and therefore are bound to ke ep your personal data in confidence.  
Your Rights – for Europe only  
You may be entitled under applicable law to ask Teva for a copy of your information, to correct it, erase or 
restrict its processing, or to ask us to transfer some of this information to other organizations. You may 
also have rights to object to some processing. These rights may be limited in some situations – for 
example, where we can demonstrate we have a legal requirement to process your personal data.  
You are not required to provide your personal data, un less you wish to do so. However, if you decide not 
to provide your personal data, we may not be able to  perform the activities described under section “How 
we use your information”.  
You have an absolute right to opt-out of processing for direct marketing purposes at any time. You can do 
this by [CONTACT_532036].  
If you have any concerns about how we process your personal data or wish to exercise any of your rights 
or wish to obtain other information, such as a copy of  a legitimate interests balancing test, you can get in 
touch with Teva’ s Data Protection Office by [CONTACT_442642] . If you live in Europe, you can contact [CONTACT_532037] [EMAIL_10170] .  For all other regions, please contact [CONTACT_7477] [EMAIL_10171] .  We 
hope that we can satisfy any queries you may have about the way in which we process your personal 
data. However, if you have unresolved concerns you also have the right to complain to the data protection 
authority in the location in which you live, work or believe a data protection breach has occurred.  
International Transfers  
Teva operates internationally and will transfer your information to the recipi[INVESTIGATOR_531982] ‘Sharing  
Your Personal Data’ section in countries outside your own country and outside the European Economic 
Area, including to the [LOCATION_006], Israel and the [LOCATION_002] . When transferring your information to Israel, Teva 
relies on the European Commission’s adequacy de cision with respect to the transfer of data from the 
European Union to Israel; when transferring to other countries outside the EEA that are not subject to an 
"adequacy decision" by [CONTACT_532038], Teva generally relies on EU Commission 
approved standard contractual clauses.  Information on the relevant mechanism can be provided upon 
request to [EMAIL_10172] . 
Electronic Records and Electronic Signatures  
Specifically, these electronic systems must comply with Title 21 of the Code of Federal Regulations 
(21CFR Part 11) relating to electronic records and electronic signatures. This affidavit is required for each 
employee using an electronic signature [CONTACT_532046]/her use of electronic signatures.  
Please read this affidavit and sign below to signify that you have read and understood this affidavit.  
Pursuant to Section 11.100 of Ti tle 21 of the Code of Federal Regulations, the undersigned hereby 
[CONTACT_532039]/her electronic signature [CONTACT_532047]/her traditional 
handwritten signature.  
  
Changes to this Notice  
This Notice may change from time to time. Teva will place an updated version of the Notice on this page 
and may otherwise communicate changes as appropriate.  
Updated: May 2021  